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Tiivistelmä 
 
Primaarinen immuunipuutos (Primary immunodeficiency disease, PIDD) käsittää joukon kliinisesti ja 
immunologisesti heterogeenisiä tautitiloja, jotka periytyvät mendelöivästi. Noin 300 geeniä on 
yhdistetty niiden kehittymiseen. Ilmiasut vaihtelevat kapeakirjoisesta herkkyydestä tietylle 
patogeenille (esim. herpesenkefaliitti) laajaan ja vaikeaan infektioherkkyyteen tai yleistyneeseen 
autoimmuniteettiin. Immuunivajavuuksien diagnostinen haaste on, että saman geenin mutaatiot 
voivat tehdä hyvin erityyppisiä kliinisiä ilmiasuja samankin perheen jäsenelle. Toisaalta 
samankaltaisen taudin voi aiheuttaa hyvin monta eri geenivirhettä. Tyypillinen geenidiagnostiikka, 
jossa diagnoosia etsitään yhdestä geenistä kerrallaan, on näin ollen taudeissa vaikeaa. 
Tässä tutkimuksessa on kuvattu kolme geneettiseltä pohjaltaan uudenlaista immuunipuutosta: 
STAT3 -proteiinin ylitoiminnan aiheuttama monen elimen autoimmuniteettioireyhtymä, sekä 
DOCK2- ja HYOU1 -puutoksen aiheuttama yleistynyt infektioherkkyys (ns. 
yhdistelmäimmuunivajavuus). Geenimuutokset löydettiin eksomisekvensoinnilla. 
Tutkimuksen ensimmäisessä ja toisessa osassa kuvataan kuuden potilaan kohortti, jossa kliinisenä 
kuvana on monen elimen autoimmuniteetti, hypogammaglobulinemia ja lymfoproliferaatio. Yhdellä 
potilaalla on lisäksi teini-iässä alkanut mykobakteeritauti. Kolme potilaista karakterisoitiin 
immunologisesti. Kaikilla on perifeerinen eosinopenia yhdistettynä luuydineosinofiliaan, Th17-
solupuutos, NK-solupuutos, ja dendriittisolupuutos. Kahdella potilaalla on säätelijä-T-solujen (Treg) 
puutos. Yksi potilaista kehitti LGL (large granular lymphocyte) -leukemian teini-iässä, ja toisella oli 
LGL-soluja luuytimessä ilman kliinistä tautia. Kaikilla on STAT3 -proteiinissa aminohappomuutos, 
joka lisää proteiinin transkriptionaalista aktiivisuutta lusiferaasireportterilla mitattuna. 
Tutkimuksen kolmannessa osassa löydettiin DOCK2-geenin resessiiviset mutaatiot suomalaiselta 
lapselta, jonka oireena olivat invasiiviset virus- ja mykobakteeri-infektiot sekä lievä hematologinen 
autoimmuniteetti. Samoihin aikoihin neljä samanlaista potilasta identifioitiin itsenäisesti myös 
Yhdysvalloissa, Ranskassa ja Itävallassa, ja kohortti julkaistiin yhtenäisenä tutkimuksena. Kaikilla 
potilailla oli selkeä lymfopenia sekä puutteellinen T- B- ja NK-solutoiminta. Tauti on fataali ilman 
kantasolusiirtoa. 
Viimeisessä osassa kuvataan vaikeista bakteeri- ja herpesinfektoista sekä lapsuusiän toistuvista 
hypoglykemioista kärsivä potilas. Immunologisesti potilaalla todettiin syvä granulosytopenia, 
anemia, B- ja dendriittisolupuutos. Potilaalla todettiin HYOU1-geenin resessiiviset mutaatiot, joiden 
osoitettiin johtavan epänormaaleihin proteiini-interaktiohin. Potilaan neutrofiilinen ja fibroblastien 
hapetustasapaino oli epänormaali, ja solulimakalvoston stressivaste poikkeava. 
Tutkimus osoittaa, että uudet sekvensointimenetelmät kuten eksomisekvensointi soveltuvat hyvin 
immuunivajavuuksien diagnostiikkaan. Näillä menetelmillä on mahdollista löytää geenimuutos 
tapauksissa, joissa affisioituneita on vain yksi. Tutkimus vahvistaa kliinisen toteaman, jonka mukaan 
immuunivajavuuksien kliininen kuva on hyvin vaihteleva. Tutkimus on lisäksi löytänyt geenejä, joita 
ei aiemmin ole yhdistetty immunologiaan tai ihmisen immunologisiin häiriöihin, ja laajentaa näin 
ymmärrystämme immuunijärjestelmän toiminnasta. 
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Abstract 
 
Primary immunodeficiency diseases (PIDD) compromise a heterogeneous group of clinical entities, 
ranging from isolated susceptibility for certain pathogen to widespread, early-onset infections or 
overwhelming autoimmunity. Although rare, PIDDs cause significant morbidity and mortality. Over 
300 genes are associated with PIDD development, and multiple gene defects can cause a similar 
phenotype. On the other hand, phenotypes caused by the same mutation can vary considerably 
even between family members. Therefore, genetic diagnostics in PIDD is challenging with standard 
candidate gene approach. 
In this study, three novel primary immunodeficiency conditions are characterized: early-onset multi-
organ autoimmune disease caused by STAT3 hyperactivity, combined immunodeficiency as due to 
DOCK2 deficiency, and generalized infection susceptibility caused by recessive HYOU1 mutations. 
The mutations were discovered using exome sequencing. 
In the first and second part of this study, the authors studied a cohort of six patients with missense 
STAT3 mutations that were shown to be activating by luciferase reporter assay. The patients 
presented with multi-organ autoimmunity that commonly started in infancy. Additionally, some had 
lymphoproliferation and developed hypogammaglobulinemia in their teens, and one patient had 
delayed-onset mycobacterial disease. Three patients were immunologically characterized. They 
showed peripheral eosinopenia and deficiency of regulatory T cells, T helper 17 cells, NK cells, and 
dendritic cells. Notably, one patient developed large granular lymphocyte (LGL) leukemia at age 14 
and another had LGL cells in her bone marrow without clinical disease. 
In third part of the study, compound heterozygous DOCK2 mutations were identified in a patient 
that showed mild hematological autoimmunity and susceptibility to bacterial and viral infections. 
Four additional patients with a similar phenotype and homozygous DOCK2 mutations were 
subsequently independently identified in four additional research groups in US, Austria, and France. 
All patients showed profound lymphopenia with defective B, T and NK cell responses, and invasive 
viral and bacterial infections that were fatal without stem cell transplantation. 
Finally, a patient with anemia and combined deficiency of granulocytes, B cells and dendritic cells 
was studied. She presented with severe early-onset bacterial and herpetic infections and stress-
induced hypoglycemic episodes. She was found to harbor compound heterozygous mutations in 
HYOU1, an endoplasmic reticulum chaperone, and the mutations altered HYOU1 substrate binding 
specificity. The defective HYOU1 function compromised the redox balance in patient neutrophils 
and skin fibroblasts, and led to altered endoplasmic reticulum stress response.  
This study shows that next generation sequencing tools such as exome sequencing are powerful in 
PIDD diagnostics. With these techniques it is possible to identify causal variants even in situations 
where only a single individual is affected. The results show that monogenic immunological 
conditions have considerable phenotypic variation even between patients with similar gene defects. 
The study also identifies novel genes with previously undescribed roles in human immunity, and 
broadens the general understanding of human immunobiology. 
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Introduction 
 
Primary immunodeficiency diseases (PIDD) are a group of hereditary diseases with diverse clinical 
manifestations and outcomes. Their frequency is estimated to be 6-10/100 000 (Bousfiha et al., 
2013). The severity of PIDDs vary considerably: some cause a broad, profound immunodeficiency 
that is fatal in infancy whereas others only lead to a narrow susceptibility to a certain pathogen and 
become evident in adulthood. 
The genetic diagnostics of PIDD is challenging. Over 300 genes are associated with PIDD 
development, and multiple gene defects can cause a similar phenotype. As an example, severe 
combined immunodeficiency (SCID) can be caused by recessive defects in approximately 50 
different genes (Rivers & Gaspar, 2015). On the other hand, phenotypes caused by mutations in a 
specific gene can vary considerably. As an example, dominant activating mutations in STAT1 can 
cause either isolated mucocutaneous candidiasis or fulminant multi-organ autoimmunity requiring 
stem cell transplantation (Liu et al., 2011; Uzel et al., 2013). Recessive loss-of function STAT1 
mutations, in turn, cause lethal mycobacterial disease (Dupuis et al., 2003). Even between members 
of the same family presentations can vary considerably. Therefore, standard candidate gene 
approaches are often unsuccessful and patients go undiagnosed. This is problematic, because the 
genetic diagnosis affects care decisions and genetic counselling. 
Next generation sequencing techniques, such as whole exome and whole genome sequencing, have 
become popular research tools in 2010’s and are currently entering into clinical use. They’re mostly 
utilized in cancer genotyping and diagnostics of monogenic diseases; in these conditions, results 
have potential to directly affect patient care. Large-scale sequencing has also allowed the 
identification of novel causative genes in situations where there is only a single affected patient – 
previously, this required large case series. As a result, novel Mendelian gene defects are currently 
published on a weekly basis. 
The aim of this study was to test the applicability of next-generation sequencing techniques in PIDD 
diagnostics by sequencing patients with genetically undefined immunodeficiency. The study also 
sought to discover novel causative genes for immunodeficiency diseases, and broaden our 
understanding on human immunobiology by phenotyping the patients in detail. 
  
16 
Review of the literature 
 
1. Primary immunodeficiency diseases 
1.1 Overview of primary immunodeficiency diseases 
Primary immunodeficiency diseases (PIDD) are a group of monogenic diseases of the immune 
system. Their frequency is estimated to be 6-10/100 000 (Bousfiha et al., 2013), and approximately 
300 genes are associated with different PIDDs (Al-Herz et al., 2014). 
Traditionally, PIDDs have been viewed as rare childhood diseases with debilitating outcomes. 
Patients who weren’t suitable for allogeneic stem cell transplantation experienced significant early 
morbidity and mortality (Murphy, 2011). Moreover, PIDD was mainly thought to be associated with 
severe immunodeficiency, and overt autoimmunity or malignancy was not perceived as primary 
manifestation of PIDD (Murphy, 2011) As the genetic basis for diverse immunological syndromes 
have been elucidated, the scope of PIDD has broadened (Al-Herz et al., 2014). Today, many PIDDs 
that involve autoimmunity as primary feature have been described; examples include APECED 
syndrome due to defective central tolerance (Finnish-German, 1997; Todoric, Koontz, Mattox, & 
Tarrant, 2013), and IPEX and IPEX-like syndromes caused by defects in regulatory T cell function 
(Todoric et al., 2013; Verbsky & Chatila, 2013). Autoimmune lymphoproliferative syndrome, on the 
other hand, primary manifests as lymphadenopathy and splenomegaly due to defective lymphocyte 
apoptosis, and does not involve significant infection susceptibility (Teachey, 2012). 
PIDDs may also have very mild symptoms, or primarily manifest in adulthood or late childhood. In 
some diseases, hypomorphic mutations that allow some normal protein function lead to milder 
adult presentations, whereas full loss-of-function leads to severe childhood-onset disease (Halbrich, 
Ben-Shoshan, & McCusker, 2013; Moshous et al., 2003). Other conditions that involve only isolated 
susceptibility to certain pathogen (ie. Candida species or herpes encephalitis) might also become 
evident only later in life (Puel et al., 2012; S. Y. Zhang, Abel, & Casanova, 2013). Even certain 
complement deficiencies, bone marrow failure syndromes and common variable immunodeficiency 
(CVID) usually manifest in adulthood (Babushok & Bessler, 2015; Cunningham-Rundles, 2010; 
Pettigrew, Teuber, & Gershwin, 2009; Zipfel & Skerka, 2009).  In the future, more adult-onset PIDDs 
that resemble common immunological diseases, such as myelodysplasia, systemic lupus 
erythematosus or vasculitis, will likely be identified. 
The frequency and spectrum of PIDD in Finland has not been extensively evaluated; however, clinical 
experience suggests it to have unique features when compared to other Caucasian populations. For 
example, common variable immunodeficiency  is approximately 3 times more common in Finnish 
than in other Caucasian populations (0.8/10 000, ESID/PAGID criteria, less than 50% of PnP 
serotypes reach level above 0.35, HUCH District, data on file). The Finnish population has a typical 
founder structure with frequent bottlenecks and genetic isolates, making it distinct from other 
European nations. This has resulted in skewed spectrum of monogenic diseases, with relatively high 
frequency of recessive syndromes known as Finnish inheritance diseases and near absence of 
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“common” genetic diseases such as phenylketonuria or cystic fibrosis. (Marjo Kestilä, 2010). It is 
possible that a similar trend is present in Finnish PIDDs. 
1.2 Primary immunodeficiency disease classification 
Primary immunodeficiency diseases can be classified to eight major categories as presented in Table 
1. The classification is made and revised at International union of immunological societies expert 
committee. It is mainly based on the affected immunological compartment, clinical presentation, 
and molecular pathogenesis of the disease. (Al-Herz et al., 2014). 
It is common that PIDDs with very different genetic etiologies may have overlapping symptoms. For 
example, a similar IPEX-like autoimmune disease can be caused by mutations in FOXP3, STAT1, and 
STAT5b that are transcription factors, or LRBA which is autophagy inducer at vesicular system 
(Lopez-Herrera et al., 2012; Verbsky & Chatila, 2013). On the other hand, mutations in a same gene 
can cause different phenotypes, such as in the case of STAT1. There, gain-of-function mutations 
cause mild mucocutaneous candidiasis or severe IPEX-like disease, and loss-of-function lead to lethal 
mycobacterial or viral disease (Dupuis et al., 2003; Liu et al., 2011; Uzel et al., 2013). This is 
insufficiently appreciated in current classification. As more PIDDs are being discovered, the 
classification might undergo a major revision.Table 1. Primary immunodeficiency disease 
classification (adapted from Al-Herz et al. (Al-Herz et al., 2014)). 
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Combined immunodeficiencies involve defects in both T and B lymphocytes; even other cell types 
may be affected. The patients typically present with marked susceptibility to viral and bacterial 
infections, sometimes with concomitant autoimmunity, and many require stem cell 
transplantation. If there are multisystemic manifestations such as malformations or neurological 
impairment they’re classified as Combined immunodeficiencies with systemic features.(Al-Herz et 
al., 2014; Rivers & Gaspar, 2015).  
The gene defects that mainly affect B cells cause bacterial infection susceptibility, 
hypogammaglobulinemia and sometimes B cell mediated autoimmunity. They are classified as  
 
Predominantly antibody deficiencies. These disorders –especially the so called common variable 
immunodeficiency (CVID) - account majority of PIDD patients. (Al-Herz et al., 2014; Jolles, 2013). 
Congenital phagocyte defects involve diseases where phagocyte number or function is severely 
decreased. The phagocytes might be severely reduced in number or their migration capacity 
defective leading to neutropenic infections, or their capacity to kill indigested bacteria might be 
impaired, which causes granuloma formation. The patients commonly present with severe bacterial 
infections. (Al-Herz et al., 2014; Glaubach, Minella, & Corey, 2014; Harris, Weyrich, & Zimmerman, 
2013). 
Defects in complement proteins cause variable clinical presentations, depending on which arm of 
the pathway is impaired. Some patients have just a narrow susceptibility to a certain pathogen (ie. 
Neisseria meningitides); others present with early-onset severe infections caused by many pathogen 
classes. Many patients develop systemic lupus erythematosus (SLE), and small proportion suffers 
from recurrent angioedema without excessive infections. (Al-Herz et al., 2014; Pettigrew et al., 
2009) 
Some PIDD patients have only isolated susceptibility to certain pathogens – candida spp., 
mycobacteria or viruses (ie. herpes or varicella). Majority of these are classified under defects in 
innate immunity. The category also encompasses patients with myeloid cell dysfunction that leads 
to generalized infection susceptibility. (Al-Herz et al., 2014). 
Finally, in diseases of immune dysregulation, the major impairment lies in the control and adequate 
suppression of adaptive immunity, making the immune system “hyperactive” and unable to 
distinguish between self and non-self. This leads to autoimmunity and sometimes hematological 
malignancy. The patients might also present with susceptibility to certain pathogens. If the innate 
immunity and inflammatory response are not adequately regulated, patients present with periodic 
fevers and inflammatory reactions against various organs. If untreated, this leads to accumulation 
of inflammatory protein deposits and amyloidosis. These diseases are collectively categorized as 
autoinflammatory disorders. (Al-Herz et al., 2014; Federici et al., 2015; Verbsky & Chatila, 2013).  
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1.2 Autoimmunity in primary immunodeficiency diseases 
Paradoxal as it may seem, autoimmunity is a common feature in PIDD. Several immunodeficiencies 
with autoimmunity as primary manifestation have been described; the best characterized are listed 
in Table 2. Additionally, many other PIDDs feature autoimmunity in varying degrees. The 
mechanisms leading to autoimmunity are variable; however five broad categories can be noted: 
 Defective clearance of extracellular debris 
 Failure of autoreactive lymphocytes to undergo apoptosis 
 Deficiency of regulatory T cells 
 Homeostatic proliferation of autoreactive lymphocytes 
 Dysregulated cytokine and intracellular signaling  
Commonly, more than one category is altered when autoimmunity develops. The monogenic 
autoimmune diseases typically involve defects in adaptive immunity. Additionally, there are PIDDs 
with dysregulated innate immune system that clinically resemble monogenic autoimmune 
syndromes. These are called autoinflammatory diseases. (Federici et al., 2015; Goyal, Bulua, Nikolov, 
Schwartzberg, & Siegel, 2009; Verbsky & Chatila, 2013). 
Defective clearance of extracellular debris 
During tissue injury, considerable amount of cellular waste is generated both through host cell 
damage and necrosis. The waste is cleared up by phagocytes. The process is enhanced by 
complement proteins that bind the debris. If cell debris is left in the tissues, epitopes that are 
normally intracellular and thus hidden from the immune cells are suddenly exposed to recognition 
by antigen-presenting cells and lymphocytes. The importance of debris clearance is illustrated well 
in complement deficiencies, the majority of which predispose to early-onset systemic lupus 
erythematosus (SLE) and other systemic autoimmune manifestations. (Goyal et al., 2009; Murphy, 
2011; Pettigrew et al., 2009) 
Failure of autoreactive lymphocytes to undergo apoptosis 
Lymphocytes differentiate in thymus (T cells) or bone marrow (B cells) and their survival is 
dependent on adequate signaling through their antigen receptor. During maturation, the 
lymphocytes are presented with host antigens. If the antigen receptor binds strongly to host 
structures, the lymphocyte either dies or enters into nonproliferative state (anergy). The process is 
known as clonal deletion (Murphy, 2011). In many PIDDs that involve autoimmunity, the antigen-
receptor signaling is disturbed, leading to survival in lymphocytes that bind strongly to host and 
anergy in those that have weak or no host interaction. This leads to skewed lymphocyte repertoire, 
with majority of lymphocytes being autoreactive and only minority interacting with pathogens. In 
other PIDDs – such as in autoimmune lymphoproliferative syndrome (ALPS) - all lymphocyte subsets 
are insensitive to apoptotic stimuli and both autoreactive and normal lymphocytes survive at equal 
proportions. (Goyal et al., 2009; Todoric et al., 2013; Verbsky & Chatila, 2013). 
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Deficiency of regulatory T cells 
Regulatory T cells are lymphocytes that control the inflammatory response, inhibiting it to overtly 
escalate. They also recognize autoreactive lymphocytes that have escaped clonal deletion and kill 
them. Diminished regulatory T cell function has severe consequences, often leading to systemic 
autoimmune manifestations that start in infancy and are lethal without bone marrow 
transplantation. (Murphy, 2011; Verbsky & Chatila, 2013). 
Homeostatic proliferation of autoreactive lymphocytes 
In patients with very few lymphocytes – mainly children suffering from severe combined 
immunodeficiency – the hematopoietic compartment has excess “space”. If these patients have 
lymphocytes with residual capacity to recognize epitopes and proliferate, an autoreactive T cell 
clone can rapidly expand and mount a massive immune response. The situation is worsened by the 
patients’ lack of regulatory T cells. The phenomenon is known as Omenn syndrome and resembles 
severe graft-versus-host disease that is seen in allogeneic stem cell recipients. Homeostatic 
proliferation is also important in other PIDDs that involve reduced numbers of various lymphocyte 
classes. (Honig & Schwarz, 2006; Murphy, 2011). 
Dysregulated cytokine and intracellular signaling 
Several PIDDs involve disturbed intracellular signaling as part of disease pathogenesis. However, in 
some diseases, excessive production or hyperreactivity to inflammatory cytokines cause 
autoimmune phenomena. In familial hemophagocytic lymphohistiocytosis the cytotoxic 
lymphocytes (CTL) are ineffective in killing virus-infected cells and as a result produce large amounts 
of cytokines that stimulate macrophages. These in turn stimulate CTLs. Finally, the cytokine storm 
leads to macrophages phagocytizing other blood cells (Meeths et al., 2014). In multi-organ 
autoimmune syndromes caused by activating STAT1 mutations, even small concentrations of 
proinflammatory interleukins elicit a strong intracellular response, leading to exaggerated immune 
responses. (Goyal et al., 2009; Todoric et al., 2013; Uzel et al., 2013; Verbsky & Chatila, 2013). 
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Table 2. Monogenic autoimmune diseases (Goyal et al., 2009; Honig & Schwarz, 2006; Verbsky & 
Chatila, 2013). 
Disease 
 
IPEX and 
IPEX-like 
diseases 
Omenn 
syndrome 
Autoimmune 
lymphoprolife
rative 
syndrome 
Autoimmu
ne 
polyglandu
lar 
syndrome 
Comple
ment 
deficienc
y 
Familial 
hemophagocy
tic 
lymphohistioc
ytosis 
Genes >7 RAG1/2 and 
other SCID-
causing 
genes 
>8 AIRE C1, C2, 
C3, C4-
encoding 
genes 
STX11, 
STXB2, 
UNC13D, 
PRF1  
Main 
autoimmune 
features 
Enteropathy, 
endocrinopath
y, eczema, 
lung disease 
Enteropathy, 
eczema, 
liver disease 
Cytopenias Endocrino
pathy 
SLE Cytopenias, 
fever, 
gastrointestin
al and 
neurological 
symptoms 
Mechanism Loss of 
regulatory T 
cells 
Homeostatic 
proliferation 
of 
autoreactive 
T cells 
Defective 
lymphocyte 
apoptosis 
Impaired 
presentatio
n of self-
antigens in 
thymus 
Defectiv
e 
clearance 
of 
immune 
complex
es 
Ineffective 
CTLs -> 
excessive 
cytokine 
production -> 
macrophage 
activation 
syndrome 
Immunodefi
ciency 
Infection 
susceptibility 
in some cases 
Severe 
combined 
immunodefi
ciency 
(SCID) 
None Mucocutan
eous 
candidasis 
Encapsul
ated 
bacteria 
- 
Other 
features 
Sometimes 
lymphoprolife
ration 
- Lymphoprolif
eration 
Ectoderma
l dystrophy 
- - 
Innate/adapti
ve defect 
Adaptive Adaptive Adaptive Adaptive Innate Adaptive 
IPEX, Immune dysregulation, polyendocrinopathy, enteropathy, X-linked; SCID, severe combined 
immunodeficiency; CTL, cytotoxic lymphocyte. SLE, systemic lupus erythematosus 
 
1.4 Combined immunodeficiencies 
Combined immunodeficiencies compromise a heterogenous group of diseases with defects in T and 
B cell function. Additionally, other cell types might be affected. The disorders can be grouped into 
two broad categories (Rivers & Gaspar, 2015): 
 Severe combined immunodeficiency (SCID) 
 Other combined immunodeficiencies 
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In severe combined immunodeficiency, the disease manifests in infancy with invasive fungal, viral 
and opportunistic infections and failure to thrive. The total lymphocyte count is diminished, and the 
proliferative capacity of lymphocytes is poor. The condition is lethal without stem cell transplant. 
(Rivers & Gaspar, 2015). 
Other combined immunodeficiencies encompass all diseases that do not fit the SCID diagnostic 
criteria. These children generally have milder disease course; nevertheless, many require stem cell 
transplant for long term survival. Clinical phenotype is variable. (Al-Herz et al., 2014; Rivers & 
Gaspar, 2015). 
 
1.5 Primary immunodeficiency syndromes involving neutropenia 
Neutropenia is a somewhat common manifestation in different PIDDs. It has varying causes, which 
can be grouped into following categories: 
 Primary deficiency in neutrophil maturation and function 
 Generalized bone marrow failure 
 Increased peripheral destruction of neutrophils 
 Defective neutrophil mobilization from bone marrow 
The first category encompasses patients with severe congenital neutropenia who have very low 
neutrophil count and neutropenic infections since birth. Primary neutropenia –although usually not 
as severe – might also accompany albinism. Examples include Hermansky-Pudlak syndrome (which 
features albinism, interstitial lung disease and colitis) or Chediac-Higashi syndrome (albinism and 
HLH predisposition). Patients with cyclic neutropenia usually have dominant mutations of severe 
congenital neutropenia genes, causing oscillations in neutrophil maturation and apoptosis. 
(Glaubach et al., 2014; Hauck & Klein, 2013). 
In PIDDs that involve bone marrow failure, neutropenia commonly manifests in late childhood or 
early adulthood. Usually multiple myeloid lineages are affected. (Glaubach et al., 2014; Hauck & 
Klein, 2013). 
Many PIDDs involve hematologic autoimmunity, which leads to cytotoxic reactions and peripheral 
destruction of red blood cells, platelets, and neutrophils. Typical disease examples are common 
variable immunodeficiency and autoimmune lymphoproliferative syndrome. The patients might 
exhibit multi-organ autoimmunity and additional features of aberrant lymphocyte function, such as 
hypogammaglobulinemia or lymphoproliferation. However, in some cases these PIDDs may initially 
present as isolated neutropenia. (Goyal et al., 2009; Todoric et al., 2013) 
Finally, in some PIDDs such as WHIM (Warts, Hypogammaglobulinemia, Infections, and 
Myelokathexis) the neutrophil production and function is intact, but they don’t exit the bone 
marrow adequately due to deficiency of chemotactic agents. (Al Ustwani, Kurzrock, & Wetzler, 
2014). 
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Table 3. Genetic causes of pediatric neutropenia (Boztug et al., 2014; Hauck & Klein, 2013). 
Disease Pathogenesis Genes Age at 
presentation 
Distinguishing features Cave 
Severe 
congenital 
neutropenia 
Impaired 
granulopoiesis 
Neutrophil 
apoptosis 
>8 Infants  Severe early-onset 
bacterial infections 
Malignancy in 
some gene 
defects 
Cyclic 
neutropenia 
Neutrophil 
apoptosis 
ELANE, 
HAX1 
Infants-
adults 
Cyclically rising and 
falling neutrophil counts 
- 
X-linked 
neutropenia 
Defects in cell 
cytoskeleton 
WAS Infants - - 
Neutropenia 
and albinism 
Neutrophil 
apoptosis 
>5 Infants  Light skin and hair color HLH in some 
gene defects 
Bone marrow 
failure 
syndromes 
Genomic 
instability 
>10 Older 
children, 
young adults 
Multiple myeloid 
lineages affected 
Malignancy 
predisposition 
PIDDs with 
immune 
dysregulation 
Autoimmune 
destruction 
>10 Any age Lymphoproliferation 
Hypogammaglobulinemia  
Multi-organ 
autoimmunity 
- 
WHIM Impaired 
neutrophil 
mobilization 
from bone 
marrow 
CXCR4 Infants, 
children 
HPV warts - 
Others Impaired 
granulopoiesis 
neutrophil 
apoptosis 
ohers 
>10 - Usually syndromic 
patients (excluding WAS 
gain-of-function 
mutations) 
- 
WHIM, Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome; HPV, Human 
Papilloma Virus; HLH, Hemophagocytic lymphohistiocytosis; WAS, Wiskott-aldrich syndrome 
 
1.5.1 Severe congenital neutropenia 
Severe congenital neutropenia (SCN) encompasses a group of PIDDs which involve constant and 
significant neutropenia since birth (absolute neutrophil count below 1.0). The patients present with 
early-onset, severe and life-threatening bacterial and opportunistic infections. In minority of 
patients, autoimmune manifestations such as inflammatory bowel disease are present. (Hauck & 
Klein, 2013). 
Mutations in over eight genes are currently known to cause congenital neutropenia. Most SCN 
patients have only isolated neutropenia, and other myeloid and lymphoid lineages are preserved. 
Of these patients, majority carry dominant or recessive mutations in ELANE gene. However, in 
minority of cases, other cell lines also display abnormality. (Hauck & Klein, 2013). 
SCN-causing genes can roughly be divided into two categories:  
 Genes which directly affect granulocyte differentiation and survival pathways 
 Genes that encode components of the endolysosomal system 
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The first category involves growth receptors, granulocyte-specific transcription factors, or cytokines 
(ie. CSF3R, GFI1). Most SCN-genes, however, encode components of endolysosomal system. Their 
common pathogenic mechanism is related to heightened sensitivity to endoplasmic reticulum (ER) 
stress. Since phagocytosis puts high strain on vesicular system, inability to tolerate ER stress leads 
to increased neutrophil apoptosis. (Glaubach et al., 2014; Hauck & Klein, 2013). 
The molecular mechanisms predisposing cells to ER stress are varied. The ELANE mutations lead to 
accumulation of misfolded ELANE protein, which induces unfolded protein response and 
subsequently ER stress (Grenda et al., 2007). In G6PC3 deficiency, glucose transport and metabolism 
is altered in the ER (Boztug et al., 2009; Jun, Lee, Song, Mansfield, & Chou, 2011). Other genes such 
as HAX1 and JAGN1 disturb the normal stress signaling (Boztug et al., 2014; Klein et al., 2007). These 
also have mitochondrial functions, and their dysfunction makes mitochondria hypersensitive to 
apoptotic stimuli. Finally, some genes impair vesicular transport. If the gene is also important for 
transport of melanocytic vesicles, the patients have albinism in addition to neutropenia (Hauck & 
Klein, 2013). 
 
2. STAT transcription factors  
 
The JAK-STAT (Janus kinase – signal transducer and activator of transcription) signaling pathway is 
critical for cell growth, proliferation and differentiation. It activates when a cytokine binds the JAK 
receptor, causing its dimerization and phosphorylation. This starts a signaling cascade that 
culminates into phosphorylation and dimerization of STAT transcription factors. The STAT dimer 
then translocates into nucleus and binds to its target genes, activating them. (Bromberg et al., 1999; 
Murphy, 2011) 
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Figure 1. JAK-STAT signaling. Figure from Shuai et al. (Shuai & Liu, 2003) with permission from Nature 
Publishing group. 
 
JAK-STAT signaling orchestrates hematopoietic cell differentiation. It is especially important in 
lymphoid lineage commitment and T lymphocyte differentiation. Depending on which JAK-STAT 
pathway dominates, a naïve T cell can become either T helper 1, 2, 17, or regulatory T cell (see Figure 
2). The T cell repertoire dictates immune response: prominent Th1 population drives cytotoxic 
lymphocytes and antiviral immunity, Th2 response B cells and antibody-mediated immunity, Th17 
protect mucosal surfaces and regulatory T cells promote immunosuppression. (Murphy, 2011) 
Multiple members of JAK-STAT pathway cause primary immunodeficiency diseases, ranging from 
isolated mucocutaneous candidiasis to severe combined immunodeficiency. Typically, if the defect 
lies early in the pathway (ie. in JAK3), it results in broad abnormalities in lymphocyte populations. 
When defect is lower, such as in STAT transcription factors, the defects are more specific, such as 
generalized viral infection susceptibility, or increased frequency of mycobacterial and candida 
infections. (Al-Herz et al., 2014; Murphy, 2011) 
Members of STAT transcription factor family are also linked to development of autoimmune disease. 
Autosomal recessive STAT5b deficiency leads to multi-organ autoimmune syndrome, and so do 
activating STAT1 mutations (Uzel et al., 2013; Verbsky & Chatila, 2013). Clonal activating STAT3 
mutations have also been shown to be present in 40-70% of large granular lymphocyte leukemia, a 
neoplastic disease that involves autoimmune manifestations (rheumatoid arthritis, autoimmune 
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cytopenias), and particularly aggressive LGL variants have shown to carry activating STAT5b 
mutations (Koskela et al., 2012; Rajala et al., 2013). Additionally, polymorphisms in STAT3 have also 
been linked to many common autoimmune diseases, including multiple sclerosis and inflammatory 
bowel disease (Jakkula et al., 2010; J. Zhang et al., 2014). Thus, disturbed signaling of STAT1, STAT3 
and STAT5b predispose to autoimmunity. 
 
 
 
 
Figure 2. T helper cell differentiation in response to different cytokines and STAT transcription factors 
(Murphy, 2011; O'Shea & Plenge, 2012; Povoleri et al., 2013; X. O. Yang et al., 2007; Zhu & Paul, 
2010). For the sake of simplicity, T helper subtypes where JAK-STAT signaling has been insufficiently 
studied were omitted. APC, Antigen presenting cell; Treg, regulatory T cell; Th, Effector T helper cell. 
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3. Next generation sequencing techniques and their clinical use 
3.1 Overview of standard DNA sequencing techniques 
Next generation sequencing (NGS) refers to DNA and RNA sequencing methods that allow high-
throughput characterization of millions nucleotide fragments simultaneously in a relatively quick 
and cheap manner. With these methods it is possible to read the whole transcriptome, genome or 
exome or, for example, use it to map transcription factor binding sites (ChipSeq). The NGS 
techniques became widely used at the end of 00’s. Currently, there are multiple different 
sequencing platforms in common use. Their gross workflow and comparison to traditional Sanger 
sequencing is presented in Figure 3. (Grada & Weinbrecht, 2013). 
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Figure 3. Schematic workflow of Sanger and next generation sequencing. Left panel: In Sanger 
sequencing, the region of interest (500-1000bp) is first amplified by PCR, followed by further 
amplification using modified nucleotides that cause termination of the read. The mix is then loaded 
into a gel which separates fragments according to size. Right panel: in next generation sequencing, 
the whole DNA is first fragmented. If only selected parts (ie. exomes) are sequenced, these are then 
enriched using specific probes (not shown in the figure). Then, the DNA ends are repaired and 
adapters ligated to the DNA fragment ends (B). Finally, fragments of appropriate size (ie. 300-500 
bp) are selected for cluster generation (C). Figure by Putnetha (Punetha & Hoffman, 2013),  with 
permission from Wolters Kluwer publishing. 
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The next generation DNA sequencing process generates millions of nucleotide sequences of varying 
length. These “reads” are computationally trimmed from artefacts and aligned to a reference 
genome. In whole genome and exome sequencing, the main goal is to find repeated small 
misalignments in reads mapping to the same genomic region (ie. A to C transition, T insertion or G 
deletion), which is indicative for single nucleotide variant (SNV). (Grada & Weinbrecht, 2013). 
Currently, there are several NGS platforms available for human genome sequencing. They differ 
between read processing and size (100-1000bp), modes of genome amplification, throughput, data 
accuracy, and price. Currently, Illumina (Illumina) is the most popular; others in common use are 
Solid (Life Technologies) and 454 Sequencing (Roche). Additionally, exciting new platforms referred 
as “third generation sequencing”, such as Helicos (Pacific Biosciences) and Oxford Nanopore are 
entering the market. Competition and rapid technological development has resulted a fall in 
sequencing price, which is currently approximately 3000€ for the whole human genome. (Churko, 
Mantalas, Snyder, & Wu, 2013; Danielsson, Mun, Lordemann, Mao, & Lin, 2014; Punetha & 
Hoffman, 2013)´. 
The advantages of large scale sequencing are obvious. However, the cost – although steadily 
declining – is still high, making the large scale NGS use restricted to laboratories with secure funding. 
The data analysis is challenging and requires bioinformatics skills. The whole exome and genome 
sequencing typically cover around 85-90% of the target area, sometimes necessitating Sanger 
sequencing of the remaining uncovered areas. The methods typically find small SNVs, insertions and 
deletions but poorly detect larger genome rearrangements. The accuracy of SNV detection is 
approximately 98% if the coverage is high enough (typically >20); nevertheless, it is recommended 
that the finding is confirmed by standard Sanger sequencing. (Grada & Weinbrecht, 2013) 
The author’s experience suggests a standard human exome sequencing run with approximately 60-
80x mean coverage to produce 40 000 –80 000 SNVs, small insertions, and deletions. A human whole 
genome run with 30x coverage identifies approximately 4 000 000 variants. 
 
3.2 Exome and genome sequencing in Mendelian disorders 
In recent years, whole exome and genome sequencing have started to enter into clinical practice. 
Currently, NGS sequencing is mostly utilized in cancer genome profiling and in diagnostics of severe 
monogenic diseases. Majority of the patients are still enrolled in scientific basis, with costs covered 
by research funding but lately, insurance companies have increasingly started to reimburse the 
sequencing fees.  (Biesecker & Green, 2014; Y. Yang et al., 2013) 
In monogenic diseases, exome and whole genome sequencing have proved superior to standard 
gene testing approach (Y. Yang et al., 2013). Currently, novel monogenic diseases identified by NGS 
sequencing are being published weekly (as an example, see AJHG vol 15, issue 4/2015, which 
reported four novel monogenic diseases featuring intellectual disability, epilepsy, and bone fragility 
among the clinical presentations (Carvill et al., 2015; Nakayama et al., 2015; Niceta et al., 2015; 
White et al., 2015)).  
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Most monogenic diseases –although sometimes with relatively clear textbook presentations – 
generally have puzzling and overlapping symptoms and need several gene tests before the diagnosis 
is reached. The cost of a commercial gene test ranges between 1000-2500€,with waiting times 1-3 
months per gene. The wait can be anguishing for families and physicians alike and unnecessarily 
delay treatment decisions. On the other hand, whole exome sequencing typically costs between 
500-1000€ (excluding bioinformatics analysis) with variable turnaround time and provides data from 
>20 000 genes simultaneously.  (Biesecker & Green, 2014; Y. Yang et al., 2013). 
Monogenic diseases are caused by rare variants significantly altering the coding sequence or leading 
to drastic changes in gene expression. To find the causative variant from the wealth of data, the 
variants are filtered by population frequency, effect on protein coding and structure, and biological 
relevance (see Table 4). This approach typically results in 3-10 candidate variants for the disease. 
(Cooper & Shendure, 2011) 
Table 4. Example of filtering workflow for a patient with monogenic disease. 
Filtering step Number of variants 
Total number of small indels and SNPs  88 140 
Excluding variants in repeat regions and with poor 
quality 
76 869 
Excluding variants with minor allele frequency >1% 7605 
Variants in coding regions that have effect on protein 
amino acid composition 
1035 
Variants affecting conserved residues or predicted to 
damage protein structure or expression 
220 
Relevant inheritance pattern ~50 
Biologically relevant variants ~7 
 
3.3 Difficulties in NGS techniques 
Exome and genome sequencing, although powerful in Mendelian disease and cancer diagnostics, 
also have their limitations. The major problem is the coverage. Although large parts of exome and 
genome are sequenced, ca. 2-5% of target areas are not covered, depending on the platform. The 
areas often have structural properties such as high GC content or repetitive elements that 
compromise their amplification. Other areas, in turn, might have pseudogenes or longer repeats in 
other genomic locations, which make the computational analysis challenging. Additionally, current 
computational methods are poor at finding larger genomic rearrangements from NGS data.  
(Biesecker & Green, 2014; Cooper & Shendure, 2011; Y. Yang et al., 2013). 
The author’s experience suggests that connecting variants in known disease-causing genes to a 
phenotype is relatively straightforward. In these cases, the diagnosis is easy to make. However, if 
there are no mutations in known disease genes, proving variants causative requires extensive 
molecular biology studies. The new methods are thus powerful in the diagnostics of known 
monogenic diseases, when mutations are coding and genes don’t lie on difficult-to-sequence 
regions. However, if no candidate variants are found, NGS sequencing cannot be used for exclusion 
of a genetic disease. (Biesecker & Green, 2014; Cooper & Shendure, 2011; Y. Yang et al., 2013). 
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The large scale sequencing approach even raise ethical questions. These mainly relate to incidental 
findings (ie. genetic variants that don’t contribute to the observed phenotype but might have other 
health consequences). For example, an individual who was sequenced due to a neurological disease 
might carry BRCA1 mutation that predisposes to breast cancer. Similarly, a person with multi-organ 
malformation syndrome might also carry a variant that significantly predisposes to early-onset 
Alzheimer’s disease. In patients with severe monogenic conditions, the need for a diagnosis 
outweighs these concerns. However, if healthy or only mildly affected relatives are sequenced, these 
issues should be discussed beforehand. (Biesecker & Green, 2014; Cooper & Shendure, 2011; Y. Yang 
et al., 2013). 
 
3.4 Clinic and laboratory collaboration in next generation sequencing 
For the large scale sequencing efforts to be successful, collaboration between the physician and 
bioinformatician is necessary. The sequencing typically yields several pathogenic-looking variants in 
known disease genes and their prioritization is made by comparing patient phenotype to the 
biological function of the gene. Thus, the patients need to be well phenotyped and their family 
history adequately taken. For example, it is not enough to state that the patient is mentally retarded; 
a comprehensive evaluation of cognition and neurologic status is needed along with brain magnetic 
resonance imaging and any abnormalities in other organ systems or general physical examination 
need to be mentioned in the referral. (Biesecker & Green, 2014; Y. Yang et al., 2013) 
Ideally, the patients would first be evaluated by a clinical geneticist who is familiar with NGS 
techniques. The family should be adequately counselled about the nature of the method, and the 
possibility of incidental findings (ie. mutations leading to breast cancer susceptibility) should be 
discussed and decided whether these are reported to the family. On the other hand, the person 
analyzing the NGS data should have adequate clinical and molecular biology knowledge to assess 
the variants. (Biesecker & Green, 2014; Cooper & Shendure, 2011; Y. Yang et al., 2013). 
 
3.5 Next generation sequencing approach in PIDD diagnostics 
The genetic diagnostics of PIDD has long been challenging. A certain immunodeficiency phenotype 
can be caused by multiple genes: for example, recessive mutations in more than 50 different genes 
are known to result in severe combined immunodeficiency (SCID) (Rivers & Gaspar, 2015). On the 
other hand, mutations in a same gene can lead to different phenotypes even between members of 
the same family. As an example, STAT1 gain-of-function mutations sometimes result in mild 
mucocutaneous candidiasis and in other cases lead to multi-organ autoimmune disease requiring 
hematopoietic stem cell transplantation (HSCT) (Dupuis et al., 2003; Liu et al., 2011; Uzel et al., 
2013). In all PIDD cases where HSCT is considered, the genetic diagnosis affects the pre-transplant 
conditioning regimen (Chiang et al., 2013). Sometimes PIDD presents as an emergency and rapid 
diagnosis is necessary for adequate treatment. For these reasons, candidate gene approach in PIDD 
diagnostics is often challenging (Slatter & Cant, 2011). 
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The advent of next generation sequencing has transformed PIDD diagnostics and currently, novel 
causative genes are published monthly. From all monogenic diseases, PIDDs are especially suited for 
next generation sequencing. Because the relevant cell type is easily available through blood 
sampling, they can be phenotyped in great detail. Additionally, if a novel candidate gene is found, it 
can easily be functionally evaluated using peripheral blood leukocytes.  
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Aims of the study 
 
The aims of this study were 
a) to test the applicability of next-generation sequencing techniques in the diagnostics of 
monogenic immunological diseases 
b) to find new causative genes for patients with unknown primary immunodeficiency and, 
c) to increase our understanding of basic immunology by detailed phenotyping of  patients 
with novel mutations in PIDD candidate genes. 
Additionally, general applicability of NGS diagnostics in clinical practice was evaluated. Whole 
genome and whole exome sequencing technologies and platforms were compared in terms of data 
quality and coding sequence coverage. Novel technologies, including STRT RNA sequencing, were 
also tested for downstream functional analyses.  
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Methods 
 
 
4. Patients 
 
Patients were collected from five Finnish university hospitals: Helsinki University Central Hospital, 
Turku University Hospital, Tampere University Central Hospital, Kuopio University Hospital, and Oulu 
University Hospital. Patients with genetically undefined primary immunodeficiency disease were 
eligible to enroll. This study was conducted in accordance to the principles of the Helsinki 
Declaration and was approved by the Helsinki University Central Hospital Ethics Committee. Written 
informed consent was obtained from all patients and healthy controls. Overview of patients is 
presented in Table 5. 
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Table 5. Overview of the studied patients. 
BM, Bone Marrow; VSV, Vesicular stomatitis virus; EMCV, Encephalomyocarditis virus 
Patient Ethnicity Clinical phenotype Mutated 
gene 
Sequencing 
method 
Immunological 
profiling 
Other 
1 Finnish Multi-organ 
autoimmunity, 
lymphoproliferation, 
growth failure 
STAT3  Exome 
sequencing 
Full T, B and NK 
cell phenotyping 
Luciferase assay, 
pSTAT3 staining 
of BM slides 
2 Finnish Multi-organ 
autoimmunity, 
lymphoproliferation, 
growth failure 
STAT3  Candidate 
gene 
sequencing 
Full T, B and NK 
cell phenotyping 
Luciferase assay, 
pSTAT3 staining 
of BM slides 
3 Serbian Multi-organ 
autoimmunity, 
growth failure 
STAT3  Exome 
sequencing 
- Luciferase assay 
4 British Neonatal diabetes STAT3  Candidate 
gene 
sequencing 
- Luciferase assay 
5 British Multi-organ 
autoimmunity, 
growth failure 
STAT3  Candidate 
gene 
sequencing 
- Luciferase assay 
6 Finnish Mycobacterial 
disease, 
autoimmunity, 
lymphoproliferation,  
STAT3  Exome 
sequencing 
Full T and B cell 
phenotyping 
STAT1/IFNy axis 
profiling 
7 Lebanese Invasive bacterial 
infections 
DOCK2  Exome 
sequencing 
T and B cell 
chemotaxis, NK 
cell phenotyping, 
PBMC IFN-α/λ 
production 
Fibroblast 
response to VSV 
and EMCV 
infection 
8 Finnish Viral and 
opportunistic 
infections 
DOCK2  Exome 
sequencing 
T and B cell 
chemotaxis, NK 
cell phenotyping, 
PBMC IFN-α/λ 
production 
Fibroblast 
response to VSV 
and EMCV 
infection 
9 Turkish Invasive viral 
infections 
DOCK2  Exome 
sequencing 
- Fibroblast 
response to VSV 
and EMCV 
infection 
10 Turkish Viral and 
opportunistic 
infections 
DOCK2  Exome 
sequencing 
- - 
11 Hispanic Invasive bacterial 
infections 
DOCK2  Exome 
sequencing 
- - 
12 Finnish Bacterial and 
herpetic infections 
HYOU1  Exome 
sequencing 
Full T and B cell 
phenotyping, 
monocyte and 
dendritic cell 
activation analysis 
Electron 
microscopy, mass 
spectrometry, 
RNA sequencing, 
metabolic 
profiling 
 
 
 
  37 
5. DNA and RNA extraction 
DNA and RNA was extracted from blood or salivary samples using commercial kits (E. M. Haapaniemi 
et al., 2015). 
 
6. Cell separation methods and cell culture 
6.1 Selection of γδ T cells (II) 
The CD3+γδ+ cell fraction was sorted from fresh peripheral blood mononuclear cells by flow 
cytometry, based on CD3, CD8, CD3, T-cell receptor-αβ (TCR-αβ), and TCR-B-γδ expression. (E. M. 
Haapaniemi et al., 2015). 
6.2 Granulocyte isolation (IV) 
Fresh blood samples were centrifuged to separate plasma and blood cells. The remaining cells were 
mixed with 6% dextran in 0.9% NaCl and then allowed to settle for 30 minutes at room temperature. 
The Leukocyte fraction was collected, washed, and subjected to Ficoll gradient centrifugation. The 
PMBC layer and granulocyte fraction was collected separately and red blood cells lysed with lysis 
buffer (for detailed account see (E. Haapaniemi, et al., 2015)). The remaining granulocytes were 
resuspended with Hanks balanced salt solution until use. (E. Haapaniemi, et al., 2015). 
6.3 Fibroblast cultures (III-IV) 
Fresh skin biopsies were cut into small pieces. Then, the cells were transferred to 12 well plates 
containing growth medium. The cells were grown for 2-3 weeks, then split onto Petri dishes and 
frozen for later use when 80% confluent. (E. Haapaniemi, et al., 2015). 
6.4 Generation of inducible HYOU1 cell lines (IV) 
Flp-In™ technology was used to create the WT and mutant streptavidin-tagged HYOU1 expressing 
cells (Life Technologies). The Flp-In™ 293 T-Rex cells were transfected with vectors that contained 
WT, p.Y231H and p.A419P mutant HYOU1 sequences using Fugene (Roche) HD according to 
manufacturer’s instructions. The cells were cultured for 2-3 weeks according to manufacturer’s 
instructions (Life Technologies). The stable expression of mutant and WT tagged HYOU1 upon 
tetracyclin induction was confirmed by western blotting. (E. Haapaniemi, et al., 2015). 
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7. Sequencing methods 
7.1 Exome sequencing from whole blood, saliva, and γδ T-cell fractions (I-IV) 
Whole exome sequencing was performed either at the Science for Life laboratory Stockholm, 
Institute for Molecular Medicine Finland (FIMM) sequencing core facility, and University of Exeter 
according to established laboratory protocols. Libraries were sequenced with 101 bp read length 
(HiSeq1500 or 2500 sequencing platform, Illumina) with mean coverage of 60-80x. 
The WES data were analyzed using an in-house procedure developed at FIMM, which is described 
in detail in (E. M. Haapaniemi et al., 2015). Briefly, Raw illumina reads were first merged with and 
low-quality reads removed. Then reads were aligned to the genome (GRCh37/Hg19). Potential PCR 
duplicates and reads mapping to multiple genomic locations were removed. In variant calling, any 
call with ratio smaller than 0.2 was assumed to be homozygous and rest heterozygous. 
All the non-coding and common variants (population frequencies above 0.01 in the general 
population) were discarded. The rare variants affecting the coding regions were filtered based on 
the predicted consequences at the transcript level. The variants were prioritized according to 
population frequency and the predicted effect on the protein. The potential consequences were 
defined according to the conservation of the affected amino acids and in silico predictions. 
7.2 Validation of candidate mutations (I-IV) 
The candidate mutations were verified by capillary sequencing from blood and salivary DNA samples 
using BigDye Chemistry (Applied Biosystems). The primers are listed in Table 6. 
  
 
 
  39 
Table 6. Primers used for genomic amplification. 
Primer name Sequence 
STAT3 
STAT3-K658N rev CAACATGTCATTTGCTGAA  
STAT3-K392R fwd CTTCATCCTCCGGCTACTTG  
STAT3-K392R rev CTGCTCCCTCAGGGTCTGTA  
STAT3-M394T fwd GAGCTCCTCCCACATACCAA  
STAT3-M394T rev CTTCATCCTCCGGCTACTTG  
DOCK2  
DOCK2-R1104W fwd TCGCCGAACTGTTTTATGTG 
DOCK2-R1104W rev GCCTCTCAATGAAGCTCAGG 
DOCK2-Q1324* fwd TGTCTTCACCAAGGCCTCTT 
DOCK2-Q1324* rev AAGCATAGAAGGACCGCTGA 
HYOU1  
HYOU1 A419P fwd CTA GAG CGC TTG GCT GAG TT 
HYOU1 A419P rev ATG GGG TAG ACC ACT GCA TC 
HYOU1 Y231H fwd CCC CTG TTG GAG CTG TTT AG 
HYOU1 Y231H rev ACC CCT GAC TTG AGG GTC TT 
 
7.3 RNA-sequencing (IV) 
Cultured primary fibroblasts were plated in 6-well plates. The following day, the cells were mock-
treated or Tunikamycin-stimulated (1ng/µl) for 1h and after that, RNA was extracted. All samples 
were studied in biological triplicates and technical replicates. (E. Haapaniemi, et al., 2015) 
RNA sequencing was performed using STRT platform and 10ng RNA as starting material. Published 
STRT protocol was applied with minor modifications (E. Haapaniemi, et al., 2015; Islam et al., 2014). 
The sequencing was performed at Illumina platform. After the sequencing, the reads were 
processed by STRT prep package. Low quality reads and PCR duplicons were excluded from the 
analysis. The reads were trimmed and separated by the barcodes as described (Kivioja et al., 2012). 
After that, they were aligned to GRCh37/hg19 genome, human ribosomal DNA unit (Trapnell, 
Pachter, & Salzberg, 2009). The expression levels were estimated by using strand-specific 50 bp 
windows and normalized to spike-in RNA. Spike-in 5’-end capture rate, endogenous polyA+ RNA 
rate, and PC1 and PC2 scores in PCA plot were used to assess sample quality. (E. Haapaniemi, et al., 
2015) 
Two deeply sequenced biological replicates in each group were selected for differential expression 
tests,. One technical replica in each biological replica were used. Fluctuated regions, which had 
broader coefficients of variation rather than technical variation of spike-in RNA, were selected 
(p<0.1 with Bonferroni correction). Finally, the significance of differential expression in the 
fluctuated regions was assessed by SAMstrt package (Katayama, Tohonen, Linnarsson, & Kere, 
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2013). Genes with reads mapping to protein-coding RNA sequence with q-value <0.1 and p<0.1 were 
considered as differentially expressed. The biological clustering and pathway analysis was 
conducted using DAVID bioinformatics database (E. Haapaniemi, et al., 2015; Huang da, Sherman, 
& Lempicki, 2009). 
 
8. Functional assays 
8.1 Plasmid mutagenesis (I-II, IV) 
The K658N, K392R, and M394T mutations were introduced into wild-type (WT) STAT3 sequence in 
pDEST40 vector using the Phusion Site Directed Mutagenesis Kit (Thermo Scientific) (primer 
sequences are shown in Table 7). The HYOU1 WT, A419P and Y231H coding sequences were 
commercially cloned into pDNR221 vector, followed by subcloning to pTO_HA_StrepIII_c_GW_FRT 
destination vector that contained the N-terminal Twin-Strep tag (Varjosalo et al., 2013). 
Table 7. Primers used in STAT3 mutagenesis 
Primer name Sequence 
STAT3-K658N fwd ATGGGCTATAACATCATGGATGCT  
STAT3-K658N rev GATGATTTCAGCAAATGACATGTTGTT  
STAT3-K392R fwd GGCACAAACACAAGAATAATGAACATG  
STAT3-K392R rev CAGAATGTTAAATTTCCGGGATCC  
STAT3-M394T fwd GAAGAATCCAACAACGGCAGC  
STAT3-M394T rev CATGTTCGTCACTTTTGTGTTTGTGC  
8.2 STAT3 Luciferase reporter assay and analysis of pSTAT3Y705 in transiently transfected cells (I-II) 
HEK293 cells that expressed firefly luciferase under STAT3-specific promoter (HEK293 GloResponse 
SIE Luc2P Hygro cells, Promega) were used. The cells were plated onto 96-well plates and 
transfected with empty, WT, or mutant STAT3 plasmids. The following day, the cells were first 
starved and after that mock-treated or stimulated with IL-6 for three hours. The luciferase activity 
was measured with the One-Glo Luciferase Assay System (Promega) according to the manufacturer’s 
recommendations. Equal plasmid transfection and STAT3Y705 phosphorylation were assessed by 
western blotting using cell lysates from parallel wells. Statistical significance was calculated using 2-
way analysis of variance. (E. M. Haapaniemi et al., 2015). 
8.3 Viral replication in fibroblasts and effects on cell viability (III) 
Skin fibroblast samples were collected from patients, processed as previously described and 
immortalized with SV40 infection. SV40-fibroblasts were plated on 24-well plates and infected with 
vesicular stomatitis virus (VSV) in DMEM medium supplemented with 2% FCS. Upon 30 min 
incubation, cells were washed and resuspended to 500 μl of cell media. Supernatants were collected 
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at different time points (2h, 8h, 16h, 24h and 48 h) and subsequently analyzed for interferon 
production using ELISA or Luminex platform as described in 9.5. (Dobbs, 2015). 
The viability of SV40-fibroblasts upon VSV or EMCV infection was assessed by resazurin 
oxidoreduction (TOX-8). Cells were plated in 96-well flat-bottomed plates in DMEM supplemented 
with 10% FCS. Next day, cells were infected in a media that contained Resazurin dye solution. The 
samples were collected after two hours, and fluorescence was measured at a wavelength of 590 
nm, with 560 nm excitation wavelength. 100% viability corresponds to the fluorescence of 
uninfected cells. (Dobbs, 2015). 
 
9. Immunological methods 
9.1 Immunophenotyping of T, B, and NK cell subsets and peripheral blood pSTAT3Y705 analysis (I-
II, IV) 
Fresh EDTA blood samples or peripheral blood mononuclear cell cultures (PBMNCs) were used for 
B and T lymphocyte immunophenotyping. The lymphocyte subsets were categorized by flow 
cytometry based on the expression of IgM, IgD, CD3, CD4, CD8, CD16/56, CD19, CD21, CD27, CD33, 
CD34, CD38, CD45, CD56, CD57, CD133, HLA-DR, CD62L, CD45, CD45RA, CD45RO, CCR7, CD25, 
CD127, and Ki-67 (Ilander et al., 2014). This allowed the characterization of T helper and T killer cells 
as well as their memory subsets, regulatory T cell number, and B cell maturation process. 
Phosphorylated STAT3 was determined by intracellular expression of pSTAT3Y705 in fresh PBMNCs. 
(Flanagan et al., 2014; E. Haapaniemi, et al., 2015; E. M. Haapaniemi et al., 2015). 
For phenotyping of IL-17–positive Th17 cells, fresh PBMCs were stimulated for 16 hours with anti-
CD3/anti-CD28 beads and Brefeldin A. After incubation, the cells were fixed and permeabilized, and 
expression of CD4, CD69, and IL-17A was determined by flow cytometry. (E. Haapaniemi, et al., 2015; 
E. M. Haapaniemi et al., 2015). 
9.2 Evaluation of Treg suppressor capacity and NK and CD3+CD8−–mediated cell cytotoxicity (II, IV) 
To evaluate Treg suppressive capacity, CD4+ T cells were first enriched from fresh EDTA blood. Then, 
CD4+ T cells expressing CD4, CD25, and CD127 were sorted using flow cytometry. The sorted cells 
were incubated for 6 days with autologous responder T cells in different ratios (1:0.5, 1:1, and 1:2), 
with anti-CD3/anti-CD28 beads as stimulus. CD4+ cells were then counted using flow cytometer. The 
suppression percentage was calculated with the following formula: 100 − ([% proliferation in 
presence of Treg/% proliferation in absence of Treg] × 100). (E. Haapaniemi, et al., 2015; E. M. 
Haapaniemi et al., 2015; Ruitenberg, Boyce, Hingorani, Putnam, & Ghanekar, 2011). 
For the assessment of T cell activation and degranulation, fresh mononuclear cells were stimulated 
for 6 hours with anti-CD3, anti-CD28, and anti-CD49d. For NK cell degranulation, cytokine and 
cytotoxicity assays, fresh mononuclear cells or flow cytometry -sorted CD3−CD16/56+ NK cells were 
stimulated with K562 (human erythroleukemia cell line) target cells for six hours. The cells were then 
analyzed based on their surface expression of CD45, CD3, CD4, CD8, CD16, CD56, CD45, CD45RA, 
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TCR-γ, CCR7, IFN-γ, and tumor necrosis factor (TNF) using flow cytometry. (E. M. Haapaniemi et al., 
2015). 
To further assess NK cell cytotoxicity, standard 4-hour chromium 51 (51Cr)-release assays were 
performed according to established protocols. Magnetic bead–separated CD3+CD8+ T-cells or 
CD3−CD56+ NK-cells were used. (Chiang et al., 2013; E. M. Haapaniemi et al., 2015; Schneider et al., 
2002). 
9.3 NK cell cytotoxicity analysis for patients 7-8 (III) 
Frozed PBMCs were thawed and incubated either overnight (K562 target cell assay) or for three days 
(P815 target cell assay) with or without IL-2 overnight. Cells were then incubated with target cells 
(K562 or P815 mastocytoma murine cell line) at an effector:target ratio of 1:2 (for K562 cells) and 
1:7 (for P815 cells) for 4 hours in culture medium supplemented with anti-CD107a-PE monoclonal 
antibody. Furthermore, various mAbs (anti-NKp30, anti-NKp46, anti-Nkp44, anti-CD16, anti-NKG2C 
or anti-NKG2D) were added to the media depending on the assay for one hour. Then, GolgiStop (BD 
Biosciences) was added at a 1:100 dilution. The cells were washed and analyzed by flow cytometry 
using CD3, CD14, CD20 and CD56 surface monoclonal antibodies. CD56+CD3-CD14-CD20- cells were 
considered NK cells, and degranulation was evaluated by counting the proportion of cells expressing 
CD107a on the cell surface. (Dobbs, 2015). 
9.4 Cytokine production (II) 
Whole blood was diluted at 1:5 in RPMI into 96-well plates. Then it was activated as indicated with 
IL-12 phytohemagglutinin, lipopolysaccharide (LPS), IFN-y, IL-18, bacillus Calmette–Guérin, phorbol 
12-myristate 13-acetate, or ionomycin. Supernatants were collected next day. Cytokines were 
measured using standard ELISA assay or multiplexed particle-based flow cytometry. The Compact 
Cytokine ELISA kit was used for IFN-y detection (Pelikine, Sanquin). Multiplexed particle-based flow 
cytometry was used to determine the plasma concentrations of TNF-α, IL-12, IL-10, IL-6, IL-17. (E. 
M. Haapaniemi et al., 2015). 
To evaluate of IFN-γ signaling in monocytes, PBMNCs were plated in flat-bottomed 96-well plates. T 
cells were stimulated with IFN-γ as indicated for one hour. Phospho-STAT1 expression was 
determined from CD14+ monocytes by flow cytometry. (E. M. Haapaniemi et al., 2015). 
For Toll-like receptor signaling assessment in monocytes, PBMNCs were stimulated with LPS or 
vehicle as indicated for one hour. L-selectin shedding was determined from CD14+ monocytes by 
flow cytometry with antibodies against CD62L and CD14. (E. M. Haapaniemi et al., 2015). 
Anti-cytokine serology was performed by multiplexed particle-based flow cytometry (see (Puel et 
al., 2010)). Serum IgG antibodies to the following cytokines were investigated: IFN-γ, TNF, IL-12, IL-
23, IFN-α, IFN-ω, IL-6, IL-17A, IL-17F, IL-22, and granulocyte macrophage–colony-stimulating factor. 
(E. M. Haapaniemi et al., 2015). 
9.5 Cytokine production in patients 7-9 (III) 
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Frozen or fresh PBMCs were seeded in RPMI medium supplemented with 10% FCS. Then, the cells 
were stimulated with either herpes simplex virus-1 (HSV-1, strain KOS-1,) or vesicular stomatitis 
virus (VSV, strain Indiana). ELISA for IFN-α, IFN-β, and IL-6 was carried out according to the kit 
manufacturer’s instructions. The IFN-λ ELISA was an in-house assay. Briefly, PBMCs were incubated 
at human IFN-λ1 coated plates for 30 min, and the IFN-λ1 concentration in the supernatant was 
measured using a secondary biotinylated anti-human IFN-λ1 monoclonal antibody. (Dobbs, 2015). 
 
To detect intracellular IFN-γ production, PBMCs were mock-treated or incubated overnight with IL-
12, IL-12 or IL-18, depending on the assay. Cells were then washed, fixed and permeabilized. IFN-γ 
production was assessed by flow cytometry from CD56+CD3-CD14-CD20- cells by subsequent 
intracellular staining with anti-IFN-γ. (Dobbs, 2015). 
 
9.6 Chemotaxis assay (III) 
PBMCs were suspended in RPMI media with 10% FCS. The cells were loaded into 5.0 μm Transwell 
inserts, and the inserts were placed onto 24-well plates that contained RPMI supplemented with 
vechile, CCL21 or CXCL12. The cells were incubated for three hours. After incubation, cells that had 
migrated to the lower chamber were collected, and analyzed by flow cytometry based on CD19 (B 
cells) and CD3 (T cells) surface expression. Results were calculated as percentage of cells that had 
migrated out of total input cells. (Dobbs, 2015). 
9.7 Monocyte and dendritic cell activation assays (IV) 
Heparinized blood samples were incubated in with LPS (100 ng/ml), Polyinosinic-polycytidylic acid 
or vehicle for one hour. The samples were then stained with surface marker antibodies CD303, CD1c, 
CD14, CD19, CD80, CD86, β7, α4,  CCR9, or an equal concentration of their corresponding isotype 
controls. The cells were fixed and analyzed by flow cytometry. (E. Haapaniemi, et al., 2015). 
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9.8 Neutrophil functional studies (IV) 
Neutrophil C5a and FMLP induced chemotaxis was assessed according to standard clinical 
procedures. To assess reactive oxygen species generation, neutrophil chemiluminescence test was 
performed according to standard protocols. (Itala, Pelliniemi, Remes, Vanhatalo, & Vainio, 1998; 
Itala, Vainio, & Remes, 1996) 
To evaluate neutrophil activation, fresh blood was stimulated with LPS or vechile for one hour, and 
stained with surface marker antibodies CD66b, CD14, CD66a, or CD11b. The cells were fixed and 
analyzed by flow cytometry. (E. Haapaniemi, et al., 2015). 
 
10. Microscopy 
10.1 Immunohistochemical staining of phospho-STAT3 and cleaved caspase-3 (II) 
Immunohistochemistry (IHC) of bone marrow biopsy paraffin sections was performed according to 
standard clinical techniques. Antibodies against pSTAT3Y705 and cleaved caspase-3 were used. Biopsy 
slides from 3 healthy individuals were used as controls. (E. M. Haapaniemi et al., 2015). 
10.2 Electron microscopy (IV) 
Granulocytes from patient and 2 healthy controls were fixed with twofold strength fixative in 1:1. 
The final fixative concentration in granulocyte suspension was 2.5% glutaraldehyde in 0.1 M natrium 
cacodylate buffer, pH 7.4. After two-hour incubation, the cells were osmicated, dehydrated in 
acetone and a graded ethanol series, and finally infiltrated gradually with Epon at room temperature 
(for detailed account see (Puhka, Joensuu, Vihinen, Belevich, & Jokitalo, 2012)). Thin sections were 
imaged by transmission electron microscope at 80 kV. The images were acquired at nominal 
magnification of 4800x using Orius SC 1000B CCD camera. The cells with at least two disguised 
nuclear profiles were chosen for further analysis. (E. Haapaniemi, et al., 2015). 
For estimation of the size and frequency of mitochondria, mitochondria and cytoplasmic area were 
manually traced in the digital images. The total cytoplasmic areas calculated were 670 µm2, 530 µm2 
and 560 µm2 for two control specimens and patient, respectively. (E. Haapaniemi, et al., 2015). 
 
11. Mass spectrometry 
11.1 Affinity purification and mass spectrometry (IV) 
Approximately 5 × 107 cells from duplicated samples were lysed in HNN lysis buffer (for detailed 
composition, see (Turunen et al., 2014; Varjosalo et al., 2013)). The proteins were bound using 
sepharose beads and Bio-Spin chromatography column (Bio-Rad), and eluted with D-biotin. 
(Turunen et al., 2014; Varjosalo et al., 2013). 
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Mass spectrometry was performed on an Orbitrap Elite ETD mass spectrometer (Thermo Scientific). 
Peak extraction and protein identification was achieved using Proteome Discoverer software 
(version 1.4.1.14, Thermo Scientific). After calibration, peak files were searched against the human 
component of UniProtKB/SwissProt database (www.uniprot.org). The biological clustering and 
pathway analysis was conducted using DAVID bioinformatics database (Huang da et al., 2009; 
Turunen et al., 2014; Varjosalo et al., 2013). 
 
11.2 Metabolomics profiling by mass spectrometry (IV) 
 
Primary cultured skin fibroblasts were plated on 6-well plates and grown to 80-90% confluency. 
Then the cells were trypsinised and washed twice using phosphate-buffered saline and finally with 
deionized water for a few seconds. The cells were then pelleted and frozen. Triplicates of each cell 
line were analyzed. (E. Haapaniemi, et al., 2015). 
For metabolite extraction, internal standard mix and cold extraction solvent (80/20 acetonitrile/H2O 
+ 1% formic acid) were added to frozen cell pellets. Cells were sonicated, vortexed and incubated 
on ice for 10 min. After centrifugation, supernatants were collected and metabolites separated using 
Waters Acquity ultra performance liquid chromatography. The analysis was made by triple 
quadrupole mass spectrometry (see (Roman-Garcia et al., 2014) for detailed account). List of 
analyzed metabolites is presented in Table 8. (E. Haapaniemi, et al., 2015). 
The enriched metabolic pathways were evaluated using quantitative enrichment analysis (QEA) 
(http://www.metaboanalyst.ca) (Xia, Mandal, Sinelnikov, Broadhurst, & Wishart, 2012). Data was 
mapped according to human metabolome database, which contains 88 metabolite sets based on 
normal metabolic pathways. (E. Haapaniemi, et al., 2015). 
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Results and discussion 
 
12. Overview of the study patients (I-IV) 
 
During the course of this study, a total of 7 patients with variable immunological manifestations 
were evaluated. Summary of their clinical, immunological and genetic findings is presented in Table 
8. 
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13. Phenotypic spectrum of gain-of-function mutations in STAT3 (I,II) 
13.1 Detection of STAT3 mutations 
Initially, two patients with early-onset multi-organ autoimmunity were evaluated for suspected 
primary immunodeficiency by two independent research groups. Exome sequencing identified 
heterozygous de novo missense mutations in positions p.K658N and p.T716M in STAT3 dimerization 
and transactivation domains, respectively. Further sequencing of a cohort of 39 neonatal diabetes 
patients identified another three STAT3-mutated patients, one with isolated neonatal diabetes and 
two with multi-organ autoimmunity. A sixth patient with adult-onset mycobacterial disease was 
independently identified through diagnostic exome sequencing. (Flanagan et al., 2014; E. M. 
Haapaniemi et al., 2015) 
Aside the p.K658N mutation which had previously been described as somatic LGL leukemia driver 
mutation (Koskela et al., 2012), all the observed missense mutations were novel and could not be 
found in any control databases (1000 genomes, NHLBI exome variant server, dbSNP and large in-
house databases). They localized to conserved amino acids and were predicted as damaging by 
various mutation prediction programs (Adzhubei et al., 2010; Kumar, Henikoff, & Ng, 2009).  
Dominant negative STAT3 mutations cause Hyper-IgE syndrome (Holland et al., 2007; Minegishi et 
al., 2007). Due to drastically different phenotypes in all observed patients, the activity of the 
mutants was tested by transiently transfecting HEK293T cells expressing luciferase under STAT3-
specific promoter with empty, wild-type and mutant STAT3 constructs. All mutants increased the 
transcriptional activity of STAT3 either constitutively or upon IL-6 stimulation (Figure 5, and 
(Flanagan et al., 2014; E. M. Haapaniemi et al., 2015)).  
The effect of mutations on STAT3 phosphorylation was studied on patient blood samples and in 
HEK293 cells transiently transfected with mutant and WT STAT3 overexpression constructs. The 
results remained inconclusive, with a slight but not statistically significant hyperphosphorylation in 
mutant samples (Figure 4 and (E. M. Haapaniemi et al., 2015)). Nevertheless, it can be concluded 
that hyperphosphorylation is not a major factor in mediating the observed transcriptional activity. 
(E. M. Haapaniemi et al., 2015). 
Soon after our study was published, a cohort of 13 patients with activating STAT3 mutations was 
reported by Milner et al (Milner et al., 2015). When comparing all the published mutations, the 
majority seem to cluster into DNA binding and SH2 transactivation and dimerization domains. These 
areas also contain mutation hotspots in Hyper-IgE syndrome (Holland et al., 2007; Minegishi et al., 
2007). 
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Figure 4. All germline activating STAT3 mutations described to date in 19 patients (Flanagan et al., 
2014; E. M. Haapaniemi et al., 2015; Milner et al., 2015). 
 
 
 
 
 
 
Figure 5. HEK293 cells containing STAT3-responsive luciferase were transfected with empty, WT, and 
mutant STAT3 overexpression plasmids with or without IL-6 stimulation (10ng/well). The studied 
mutants (K392R, M394T and K658N) significantly increased STAT3 transcriptional activity either in 
basal or stimulated conditions. Figure modified from (E. M. Haapaniemi et al., 2015). 
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Figure 6. pSTAT3Y705 phosphorylation in HEK293 cells transfected with WT and mutant STAT3-
overexpression constructs. No significant difference in phosphorylation was noted between groups. 
IL-6 concentration is 10ng/well. Empty, empty vector; WT, wild-type STAT3. Figure modified from 
(E. M. Haapaniemi et al., 2015).  
 
13.2 Clinical characteristics of STAT3 gain-of-function patients 
All the six patients with activating STAT3 mutations presented with multi-organ autoimmunity, with 
onset below 12 months of age in most cases. The most common target was the endocrine system 
(5/6), mainly pancreatic beta cells (4/6), but thyroid autoimmunity (2/6) was also seen. Another 
common target was gut (4/6). Hematological autoimmunity (autoimmune hemolytic anemia and 
immune thrombocytopenia) was seen in 3/6 cases, with onset after 10 years of age. 
The older patients developed hypogammaglobulinemia in their early teens. Furthermore, two cases 
developed lymphoproliferation. In younger patients, no infection susceptibility was reported.  
In contrast to other cases, the p.M394T patient experienced only mild, late-onset autoimmunity and 
did not need prolonged immunodulatory drug administration. She, however, developed 
disseminated mycobacterial disease in late adolescence. 
When comparing these findings to Milner cohort, autoimmune cytopenias and lymphoproliferation 
(lymphadenopathy and/or hepatosplenomegaly) were present in 80% of cases. Several patients did 
not present with early-onset multi-organ autoimmunity but instead had mild autoimmune 
lymphoproliferative syndrome (ALPS) –like clinical course. The severity did not depend on mutation 
status since patients sharing the same mutation had major differences in disease severity, even 
between family members. Likely, modifying genetic and environmental factors play a role. (Flanagan 
et al., 2014; E. M. Haapaniemi et al., 2015; Milner et al., 2015). 
Milner et al. reported a relatively high incidence of opportunistic infections, with several patients 
experiencing invasive candida and viral (varicella, herpes, human papilloma virus) infections. 
Hypogammaglobulinemia was also common. This is in line with the three Finnish patients. (Flanagan 
et al., 2014; E. M. Haapaniemi et al., 2015; Milner et al., 2015). 
Empty      WT      K392R   M394T   K658N 
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Most of the patients in this study (4/6) also had short stature, with two showing profound growth 
failure. This is in line with Milner cohort, where 7/13 patients had short stature. (Flanagan et al., 
2014; E. M. Haapaniemi et al., 2015; Milner et al., 2015). 
The alternating disease manifestations in the two cohorts are likely biased by differences in patient 
recruitment. Flanagan et al. recruited patients with neonatal diabetes, whereas Milner et al. 
collected ALPS patients. This inevitably causes bias in disease presentation. More case series 
collected from immunology, rheumatology and hematology centers are needed to better 
understand the common clinical phenotypes. 
Hyper-IgE syndrome (HIES) caused by dominant negative STAT3 mutations typically presents as 
severe eczema and susceptibility to skin and pulmonary infections (Holland et al., 2007; Minegishi 
et al., 2007). Eczema was common in our cohort but does not resemble HIES eczema either clinically 
or histopathologically. In the Milner cohort, some patients presented with invasive candida 
infections (Milner et al., 2015). No other features of HIES were noted. 
A multi-organ autoimmune syndrome has also been described in patients carrying STAT1 and 
STAT5b mutations (Uzel et al., 2013; Verbsky & Chatila, 2013). Their clinical comparison is presented 
in Table 11. The autoimmune and immunodeficiency phenotypes are indistinguishable between 
groups. However, STAT3 patients experience high degree of lymphoproliferation, which is seen 
neither in STAT1 and STAT5b defects nor in other IPEX-like syndromes.  
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Table 9. Characteristics of patients with activating STAT3 mutations. (Flanagan et al., 2014; E. M. 
Haapaniemi et al., 2015) 
 
SD, Standard deviation; M. Avium, Mycobacterium avium; TPO, thyroidea peroxidase autoantibodies; IAA; Insulin 
autoantibodies GADA, glutamic acid decarboxylase autoantibodies; ICA, islet cell cytoplasmic autoantibodies. 
 
 
STAT3 mutation K658N K392R T716M 
 
N646K 
 
N646K 
 
M394T 
Ethnicity Finnish Finnish Serbian British British Finnish 
Sex Female Female Female Male Male Female 
Age (years) 17 15 6 6 3 22 
Birthweight (SD) 0 -5 -1.6 -2.7 -1.6 0 
Growth (SD), 
puberty 
-4  
Delayed puberty 
-7  
Delayed puberty 
-2.3 -1.5 -2 0 
Normal puberty 
Infection susceptibility 
Bacteria Upper respiratory 
tract infections 
Severe dental caries  
 
Lower respiratory tract 
infections 
Severe dental caries 
- - - Lower respiratory 
tract infections 
Virus Severe varicella - - - - - 
Mycobacteria - - - - - Disseminated M. 
Avium 
Autoimmunity 
Endocrine Subclinical 
hypotyreosis with 
TPO positivity 
Neonatal diabetes with 
positive 
IAA/GADA/ICA 
autoantibodies 
Neonatal diabetes, 
no autoantibodies 
Hypothyreosis 
(TPO+) 
Neonatal diabetes, 
no autoantibodies 
Neonatal diabetes, 
no autoantibodies 
- 
Gastrointestinal Autoimmune 
enteropathy 
Coeliac disease 
 
Coeliac disease - - Lymphocytic colitis 
Skin Generalized, livedo-
like exfoliating 
dermatitis 
Eczema - Eczema Eczema Mild atopic-like 
eczema 
Pulmonary  Cryptogenic 
organising 
pneumonia, asthma-
like symptoms, 
bronchiectasis 
Desquamative 
interstitial pneumonitis 
- - - - 
Hematological Autoimmune 
hemolytic anemia 
Autoimmune 
hemolytic anemia 
- - - Immune 
thrombocytopenia 
Eye Sicca syndrome and 
bilateral posterior 
uveitis 
   Severe sicca  
Other Autoinflammation 
Sterile pleuritis or 
serositis with high 
fever and elevated 
inflammatory markers 
- -  Juvenile arthritis - 
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Figure 7. Eczema in the patient harboring K658N mutation. The appearance is different from typical 
Hyper-IgE eczema both clinically and histologically. Figure modified from (E. M. Haapaniemi et al., 
2015). 
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Figure 8. Common symptoms in STAT3 hyperactivation syndrome (n=19). (Flanagan et al., 2014; E. 
M. Haapaniemi et al., 2015; Milner et al., 2015). *Type I diabetes or hypothyroidism, ^Recurrent 
bacterial infections, or invasive candida, mycobacteria or varicella. 
 
  
0% 10% 20% 30% 40% 50% 60% 70% 80%
Cytopenias
Enteropathy
Endocrinopathy*
Lung disease
Lymphoproliferation
Infection susceptibility^
Hypogammaglobulinemia
short stature
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Table 10. Comparison of IPEX-like syndromes caused by different STAT genes (Flanagan et al., 2014; 
E. M. Haapaniemi et al., 2015; Milner et al., 2015; Uzel et al., 2013; Verbsky & Chatila, 2013). 
 STAT1 STAT3 STAT5b 
Mutation type Heterozygous gain of 
function 
Heterozygous gain of 
function 
Homozygous loss of 
function 
Autoimmunity 
Eczema ++ ++ ++ 
Enteropathy ++ ++ ++ 
Endocrinopathy ++ ++ + 
Interstitial lung disease + 
 
++ +++ 
 
Other immunological symptoms 
Lymphoproliferation - +++ - 
Cytopenias - +++ ++ 
Allergy ++ + + 
Autoinflammation - + - 
Infection susceptibility Candida, bacteria, 
herpesvirus 
Candida, mycobacteria, 
bacteria, varicella,  
Bacteria, varicella 
Other features 
Growth failure - +++ +++ 
IGF-1, IGF1BP - Normal Low 
Hypogammaglobulinemi
a 
+ +++ - 
Regulatory T cells Normal Low Low 
Cardiovascular 
manifestations 
++ + - 
Gastrointestinal 
manifestations 
Gut malrotation Rudimentary pancreas - 
 
 
13.3 Immunological aberrations in patients with gain-of-function mutations in STAT3 (II) 
13.3.1 B cells 
Three patients (p.K658N, p.K392R, p.M394T) were further immunologically characterized (E. M. 
Haapaniemi et al., 2015). The observed aberrations were mainly in lymphoid compartment (see 
Table 11). All patients had hypogammaglobulinemia. This was also common in the Milner cohort 
(Milner et al., 2015). The gross CD19+ B-cell counts were preserved, but more mature B-cell stages 
were below normal range.  
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Since STATs control helper T cell differentiation, STAT3 hyperactivity might attenuate Th2 cell 
response and subsequently favor differentiation to other helper T cell subsets (O'Shea & Plenge, 
2012). As Th2 cells promote B cell responses, this would manifest as attenuated antibody production 
(Murphy, 2011). STAT3 is downstream effector of IL-21 signaling, which is important for B cell 
differentiation into plasmablasts, and altered IL-21 signaling could also contribute (Avery et al., 
2010; O'Shea & Plenge, 2012). B cell exhaustion due to chronic inflammation might play a role as 
well (Andrews & Wilson, 2010).  
Interestingly, in patients with Hyper IgE syndrome and dominant negative STAT3 mutations, low 
memory B cells and impaired antibody responses to polysaccharide antigens have been described, 
although they generally have normal to high immunoglobulin titers (Speckmann et al., 2008). It is 
likely that for normal B cell function, all alterations in STAT3 signaling are detrimental.  
13.3.2 T cells 
The two patients experiencing early autoimmunity had reduced counts of regulatory T cells. Their 
suppressive capacity was also found impaired. The same trend was present in Milner cohort (Milner 
et al., 2015). Regulatory T cells are important in lymphocyte homeostasis, and several genetic 
defects in Treg function involve autoimmunity (Murphy, 2011; Verbsky & Chatila, 2013).  
All three patients had elevated counts of CD3+CD4-CD8- T cells, which were also noted in Milner 
patients (E. M. Haapaniemi et al., 2015; Milner et al., 2015). Elevated CD4-CD8- T cell count is a 
cardinal feature of autoimmune lymphoproliferative syndrome, and suggests defective lymphocyte 
apoptosis (Fisher et al., 1995; Rieux-Laucat et al., 1995). It has also been reported as common 
phenomenon in pediatric autoimmune diseases (Tarbox et al., 2014). Possibly, the combination of 
impaired apoptosis of autoreactive lymphocytes combined with compromised Treg function is a 
major factor in autoimmunity development. 
STAT3 is essential for Th17 cell function and maturation, and dominant negative STAT3 mutations 
lead to loss of Th17 cells (Ma et al., 2008; X. O. Yang et al., 2007). Curiously, the patients presented 
with reduced Th17 cells and impaired IL-17 secretion (E. M. Haapaniemi et al., 2015). The defective 
Th17 immunity likely underlies the candida and other opportunistic infections seen in some patients 
(Liu et al., 2011).  
13.3.3 Dendritic cells and NK cells 
The three patients in this study also had dendritic cell (DC) deficiency, ranging from reduced 
plasmacytoid DC number to a lack of all tested DC subsets. The patients also presented with reduced 
NK-cell counts; however, their function and maturation was subsequently found normal. Diminished 
DC counts and paucity of NK-derived cytokines likely contributes to the invasive viral, bacterial and 
opportunistic infections seen in our and Milner patients (Collin, Bigley, Haniffa, & Hambleton, 2011; 
E. M. Haapaniemi et al., 2015; Milner et al., 2015). 
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13.3.4 Myeloid cells 
In the myeloid compartment, peripheral eosinopenia in all 6 patients published in this study 
(Flanagan et al., 2014; E. M. Haapaniemi et al., 2015). This associated with bone marrow eosinophilia 
in two patients that were available to study. To detect eosinophil apoptosis, the bone marrow slides 
of p.K658N, p.K392R –mutated patients were stained with cleaved caspase 3 but the results were 
normal. Hence, the patients likely have impaired eosinophil mobilization from bone marrow. (E. M. 
Haapaniemi et al., 2015) 
IL-5 is produced by Th2 cells, and induces eosinophil mobilization. Pharmaceutical IL-5 blockage 
greatly reduces circulating eosinophils, keeping bone marrow eosinophil count intact (Fulkerson & 
Rothenberg, 2013). The peripheral eosinopenia could thus be attributed to the attenuated Th2 
response and the resulting fall in IL-5 secretion (Murphy, 2011; O'Shea & Plenge, 2012). IL-5 -
signaling is mediated by STAT5 and to a lesser extent by STAT3 (Fulkerson & Rothenberg, 2013; 
Schindler, Levy, & Decker, 2007). Likely, both the paucity of Th2 cytokines and the disturbed 
downstream interleukin signaling cause the observed eosinophil mobilization defect. 
 
13.4 Mycobacterial disease and STAT3 hyperactivity 
 
The patient with the M394T mutation had delayed-onset mycobacterial disease as primary disease 
manifestation. Mendelian susceptibility to mycobacterial disease sometimes presents in 
adolescence, and generally involves defects in IL-12/IFN-γ feedback loop (Cottle, 2011). Thus, the 
M394T mutated patient was extensively studied for IL-12/IFN-γ feedback loop impairments. 
However, none was found. She also tested negative for autoantibodies against various cytokines 
that are important in mycobacteria elimination (E. M. Haapaniemi et al., 2015). 
The patient, however, had low IFN-γ production upon stimulating PBMNCs with IL-12, LPS or IL-18. 
This likely reflects the low NK cell count. IFN-γ is an important cytokine in mycobacterial defence 
(Cottle, 2011). This defect, together with her low DC count, could contribute to the disseminated 
infection. 
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Table 11. Common immunological aberrations in patients with activating STAT3 mutations (n=3). (E. 
M. Haapaniemi et al., 2015) 
Immunological aberration No of patients Clinical phenotype association 
Myeloid 
Eosinopenia with bone marrow eosinophilia 2# - 
Dendritic cells ↓ 3 Invasive viral, bacterial, 
mycobacterial and opportunistic 
infections 
NK cells ↓ 3 Invasive viral, mycobacterial and 
opportunistic infections 
T cells 
CD4−CD8− elevated* 3 Lymphoproliferation, 
autoimmunity 
Treg ↓  2 Autoimmunity 
Th17 ↓ 3 Candida infections 
B cells 
Hypogammaglobulinemia 3 Bacterial infections 
Switched memory B cells low 3 Bacterial infections 
Treg, regulatory T cell; Th17, T helper 17 cell;  #Eosinopenia also present in two British and one Serbian patient 
(Table 10); *Total number, αβ or γδ subsets elevated 
 
13.5 Lymphoproliferative states caused by STAT3 gain-of-function mutations 
Clonal, oncogenic STAT3 mutations have been described in several malignancies, including aplastic 
anemia and LGL leukemia (Bromberg et al., 1999; Jerez et al., 2013; Koskela et al., 2012). In Milner 
cohort, one patient developed non-Hodgkin lymphoma, and benign lymphoproliferation was 
common (E. M. Haapaniemi et al., 2015; Milner et al., 2015). In our cohort, two patients (2/6) 
experienced marked lymphoproliferation. The patient with p.K658N mutation developed peripheral 
lymphadenopathy and splenomegaly at age 6. In lymph node biopsy, polyclonal CD4+ T-cell 
expansion was detected. The condition has since persisted.  
The second patient with p.K392R mutation developed LGL-leukemia at age 14. The expanding cells 
were mainly CD3+TCR-γδ+, with 45 % expressing CD8 and the rest having TCR-γδ+CD4-CD8- 
immunophenotype. The LGL proliferation accounted 57% of the CD3+ T-cells. The clonality of the 
LGL proliferation was confirmed by TCR-γδ receptor PCR analysis. 
No cytogenetic alterations were found in the LGL-subset in routine clinical investigations. To 
elucidate potential oncogenic single nucleotide variants (SNVs) driving the LGL expansion, the CD3+ 
TCR γδ cells were exome sequenced in parallel with the germline DNA extracted from saliva sample. 
Four novel somatic mutations were called in the following genes: LY9, RB1CC1, FOXP4 and ICOSLG. 
All mutations were classified as benign. The variant allele frequency varied between 10-17%, 
suggesting that the mutations were located in a subpopulation of TCR-γδ+ cells. No loss of 
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heterozygosity for the germline STAT3 K392R mutation was observed, and no genomic 
rearrangements were detected. 
The bone marrow biopsies from patients 1 (K658N) and 2 (K392R) and were re-evaluated and 
stained for pSTAT3Y705 immunohistochemistry. In both cases we observed increased number LGLs 
that stained positive for pSTAT3Y705. The number of pSTAT3-positive LGLs was higher in K392R 
mutated patient, likely due to her LGL leukemia. In healthy controls, pSTAT3-positive LGLs could not 
be observed.  
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Figure 9. Bone marrow biopsy shows abnormally high number of phospho-STAT3–positive 
lymphocytes both in patient with K392R mutation (A) and, to a lesser extent, in patient with K658N 
mutation. Morphologically, these cells were classified as large granular lymphocytes (LGL). Phospho-
STAT3–positive LGLs are not present in healthy bone marrow (C).Figure modified from (E. M. 
Haapaniemi et al., 2015). 
 
Based on these results, germline activating STAT3 mutations predispose to hematological 
malignancy but the effect is not as drastic as one would expect, in relation to previous knowledge 
on STAT3 function (Bromberg et al., 1999). However, patients in both our and Milner cohorts are 
relatively young, whereas cancer susceptibility might become evident only later in life. Follow-up 
studies on larger STAT3 patient cohorts will help to clarify the issue. 
It is intriguing that clonal STAT3 mutations are particularly common in large granular lymphocytic 
(LGL) leukemia, being present at 40-70% of LGL patients (Koskela et al., 2012). The symptoms of LGL 
leukemia are autoimmune cytopenias and lymphoproliferation (Koskela et al., 2012). Other 
autoimmune diseases, particularly rheumatoid arthritis, are common as well (Koskela et al., 2012). 
Thus, overlap is seen between clonal and germline activating STAT3 mutations and their shared 
pathogenesis suggests an intimate connection between immunodysregulation, autoimmunity, and 
malignancy.  
 
14. DOCK2 and combined immunodeficiency (III) 
14.1 Clinical characteristics of the index case 
The patient is a four-year old girl born to non-consanguineous Finnish parents from uncomplicated 
pregnancy. Her growth and development has been normal. From age 6 months she suffered from 
recurrent otitis media, diarrhea and an episode of pneumonia. She also experienced three episodes 
of immune thrombocytopenia in the first two years of life that resolved spontaneously. At 2.5 years 
of age, she developed vaccine strain-related varicella, with liver and lung involvement and multiple 
pulmonary infiltrates, requiring ventilatory support. Several months later, a chest computer 
tomography showed a new pulmonary infiltrate. A lung biopsy revealed granulomatous 
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inflammation with acid-fast bacilli. Mycobacterium avium was cultured from the biopsy, and human 
herpes virus-6 DNA was detected. Immunological investigations revealed T- and B-cell lymphopenia, 
defective in vitro T-cell proliferation and lack of specific antibody responses. At the age of 3.8 years, 
she received matched unrelated donor HSCT with reduced intensity conditioning using treosulfan, 
fludarabine, and alemtuzumab. She is alive and well, 8 months after HSCT. 
The clinical presentation of the patient was suggestive for combined immunodeficiency but did not 
fit to any previously described immunological disease. For diagnostic and treatment evaluation 
purposes, she underwent whole exome sequencing, which revealed compound heterozygous 
mutations in DOCK2 gene. The first missense mutation was predicted to negatively affect a 
conserved residue (see Fig 12). The second missense mutation created a premature stop codon and 
truncated protein. Her parents were heterozygous for each allele and asymptomatic. 
14.2 Detection of DOCK2 mutations 
Meanwhile, four similar patients were independently identified in four different research groups in 
US, France and Austria. All patients experienced early-onset invasive viral and bacterial infections, 
much like the Finnish index patient. All but one were products of consanguineous marriages. The 
infections were either fatal in early childhood, or necessitated hematopoietic stem cell 
transplantation (Figure 10 and Table 12). The patients were exome sequenced in respective research 
laboratories. This revealed homozygous missense or frameshift mutations in DOCK2 gene, leading 
to truncated protein or affecting conservative residues negatively. (Dobbs, 2015) 
 
 
Figure 10. Overview of the observed recessive mutations in DOCK2 protein (Dobbs, 2015). 
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Table 12. Clinical characteristics of the studied patients (Dobbs, 2015). 
Patient characteristics 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Sex Male Female Male Male Male 
Ethnicity Lebanese Finnish Turkish Turkish Hispanic 
DOCK2 
mutation 
Y1242Yfs* R1104W/Q1324* R751S F744Cfs*27 M120Mfs*22/P146L 
Current age 18 months 4 years 6 years 20 months 17 years 
Clinical 
characteristics 
Severe RSV 
bronchiolitis 
Bacterial 
pneumonia 
Bacterial 
pneumonia 
Invasive vaccine-
related varicella 
Mycobacterium 
avium pneumonia 
Immune 
thrombocytopenia 
Mumps 
meningoencephalitis 
Invasive varicella 
Colitis 
Unspecific 
inflammatory 
liver disease 
Recurrent HiB 
pneumonia 
Recurrent 
CMV 
infections 
Severe bacterial 
pneumonia 
Outcome Alive after 
HSCT 
Alive after HSCT Death at age 6 yo 
(hemorrhagic 
varicella) 
Death at age 
20 months 
(Klebsiella 
sepsis) 
Alive after HSCT 
Immunology 
T cells* low low low low low 
B cells  normal low normal low normal 
Antibody 
response to 
specific 
antigens 
- Not detectable Not detectable Not detectable Not detectable 
PHA response low low low low low 
T and B cell 
migration& 
poor poor - - - 
NK cell 
function*# 
poor poor - - - 
PBMC IFN-
α/λ 
production¤ 
poor poor poor - - 
Fibroblast 
viability after 
virus 
infection¤ 
low low low - - 
HSCT, Hematopoietic stem cell transplant; PHA, Phytohemagglutin; PBMC, polymorpohonuclear cells  
&upon stimulating with CCL21 and XCCL12, *degranulation upon stimulation with K562 cell line or after 
engagement of NK-specific receptors, #NK cell IFN- γ production upon stimulation with IL-12 and IL-18, ¤after 
in vitro herpes simplex virus type 1 (HSV-1) vesicular stomatitis virus (VSV) or Encephalomyocarditis virus 
(ECMV) infection. 
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14.3 Immunological consequences of DOCK2 deficiency 
All patients showed reduced T cell counts and defective B and T cell function. Blood and skin 
fibroblast samples from patients 1 and 2 were available for further study. In both patients, T and B 
cell migration in response to stimulation with CCL21 and CXCL12 was impaired, which is in line with 
previous data on DOCK2 function (Fukui et al., 2001). The patients had normal NK cell counts, but 
their function was compromised. Their degranulation was impaired upon stimulation with K562 cell 
as well as after engagement of various NK cell receptors (CD16, NKp30, NKp44, NKp46 or NKG2D). 
Furthermore, the IFN- γ production from NK cells after stimulation was low. (Dobbs, 2015) 
 
The PBMCs from patients 1-3 showed impaired IFN-α/λ production upon infection with herpes 
simplex virus type 1 (HSV-1) or vesicular stomatitis virus (VSV). Furthermore, fibroblasts from the 
same patients showed heightened sensitivity and increased cell death after in vitro infection of 
ECMV or VSV viruses. (Dobbs, 2015) 
 
DOCK2 knock-out mouse has previously been described, and recapitulates most of the clinical and 
immunological features seen in the patients, including impaired interferon responses and NK cell 
function (Fukui et al., 2001; Nombela-Arrieta et al., 2004; Sakai et al., 2013; Sanui et al., 2003). 
Therefore, DOCK2 seems to have a conserved immunological function at least in mammals. DOCK2 
is a cytoskeletal protein, and defects in cytoskeleton and actin dynamics have also described in other 
combined immunodeficiencies with T cell defects, such as Wiskott-Aldrich syndrome, and WIP, 
RHOH MST1 and DOCK8 deficiency (Crequer et al., 2012; Lanzi et al., 2012; Nehme et al., 2012; Su, 
2010; Thrasher & Burns, 2010). The results of this study strengthen the importance of cytoskeletal 
dynamics in T cell function. 
Recessive DOCK8 mutations cause autosomal recessive hyper IgE syndrome (Su, 2010). These 
patients present with asthma, allergy, variable autoimmunity, and cutaneous viral infections. The 
studied DOCK2 patients experienced very little autoimmunity but viral infections were invasive and 
fatal. The phenotype of DOCK8 deficiency is generally milder, with stem cell transplant considered 
only in severe cases. 
 
15. HYOU1 mutations in congenital neutropenia with combined 
immunodeficiency (IV) 
 
15.1 Clinical characteristics of the index patient 
The patient’s main clinical features are listed in Table 13. She was born small for gestational age and 
her subsequent growth was poor. After birth, she developed post-partum omphalitis and 
hypoglycemia. During childhood, the hypoglycemic episodes continued mainly during infections. 
From infancy to adulthood, she suffered from numerous septic infections of respiratory tract, skin 
and mucous membranes, necessitating intensive care several times. At age four, she had severe 
septic herpetic gingivostomatitis which necessitated intensive care and repeated parental 
granulocyte transfusions. Herpetic stomatitis subsequently recurred monthly for several years. In 
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adulthood, she contracted herpetic encephalitis followed by recurring condylomatous warts in her 
thighs and genital area. During her teenage years, relapsing suppurative hidradenitis was diagnosed. 
This cleared out spontaneously in her twenties. (E. Haapaniemi, et al., 2015) 
GM-CSF and intravenous immunoglobulin treatment were initiated when the patient was in her 
twenties. This led to the normalization of her absolute neutrophil count and significantly decreased 
the rate of bacterial infections. In her 40’s, the patient has developed relapsing Takayasu arteritis 
with positive response to rituximab and high-dose steroid treatment. Currently, the patient receives 
GM-CSF, immunoglobulin replacement therapy, rituximab, and oral prednisolone. (E. Haapaniemi, 
et al., 2015) 
 
Table 13. Overview of the index case (E. Haapaniemi, et al., 2015). 
Sex Female 
Ethicity Finnish 
Current age 44 
Endocrinology 
Growth Small for gestational age (2500g/H38) 
-2.5 to -3.2 SD 
Other Stress-induced hypoglycemia 
Infection susceptibility 
Bacteria Early-onset, septic infections (skin, mucous membranes, respiratory tract) 
Common pathogens 
Virus Recurring herpetic gingivostomatitis 
Herpes encephalitis 
Generalized herpes infection 
HPV warts 
Immune dysregulation 
Autoimmunity Suppurative hidradenitis 
Takayasu arteritis 
 
15.2 Immunological aberrations in the index patient 
The patient showed abnormalities across the whole myeloid compartment. From early infancy, she 
had constant granulocytopenia, with decreased neutrophil, eosinophil and basophil counts. The 
absolute neutrophil count  was typically 100-200 cells/mm3, with increases to near-normal limits 
during septic episodes and GM-CSF treatment. The neutrophils showed poor chemotaxis, increased 
activation, and enhanced reactive oxygen species (ROS) production. Additionally, the patient 
showed fluctuating thrombocytopenia. She also had chronic microcytic anemia with normal ferritin 
and reticulocyte levels. In bone marrow examination taken prior GM-CSF treatment, myeloid 
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maturation arrest with prominent granulopoiesis and increased neutrophil precursor synthesis was 
observed. The megakaryocyte precursors were also abnormal with increased fragmentation. The 
findings resolved upon GM-CSF therapy. (E. Haapaniemi, et al., 2015) 
The lymphoid compartment was detailed when the patient was in her twenties. She had 
rudimentary thymus and adenoid tissue. She was generally lymphopenic with diminished T cell and 
B cell counts. In T cell compartment, the proportions of CD4+ and CD8+ T cells were within normal 
range, with naive CCR7+CD45RA+ cells dominating the repertoire. The B cell count was reduced, and 
mainly consisted of mature B cells. Surprisingly, her antibody levels were within normal levels. 
However, she did not make responses to polysaccharide antigens. Upon stimulation with 
Phytohemagglutinin and Concanavalin A, the lymphocytes showed poor proliferative responses; 
however, Pokeweed mitogen stimulation evoked normal response. (E. Haapaniemi, et al., 2015) 
The patient’s plasmacytoid (pDC) and monocytoid (mDC) dendritic cells were also reduced in 
peripheral blood. The expression of co-stimulatory CD86 molecule was low in both mDCs and 
monocytes. In monocytes, we also noted decreased expression of tissue homing markers α4, β 7 
and CCR9. 
Taken together, these findings suggest a significant myeloid maturation block. It can also be 
speculated that the abnormalities in her lymphoid compartment partly stem from inefficient antigen 
presentation. This is suggested by the combination of normal immunoglobulins and absence of 
antibody response to polysaccharide antigens. In addition, most of her T cells were naive, having 
not encountered specific stimulating antigens (E. Haapaniemi, et al., 2015). Her dendritic cells are 
low, with reduced co-stimulatory molecule expression. Macrophage function was not assessed.  
 
Table 14. Overview of the patient’s immunological features (E. Haapaniemi, et al., 2015). 
Myeloid Granulocytopenia 
Microcytic anemia 
Intermittent thrombocytopenia 
Dendritic cells Low 
B cells Low 
Normal maturation 
Immunoglobulins normal 
No antibody response to polysacharide antigens 
CD4+ T cells Naive T cells dominate 
CD8+ T cells Naive T cells dominate 
Lymhoid tissue Hypoplastic thymus, rudimentary adenoids and tonsils 
Bone marrow 
examination 
Intermittent myeloid maturation arrest 
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15.3 HYOU1 mutations and their consequences to the protein structure 
The clinical and immunological phenotype did not fit into known primary immunodeficiency 
diseases, and the patient underwent whole exome sequencing to elucidate the genetic background 
of her disease. This revealed novel compound heterozygous missense mutations at hypoxia-
upregulated 1 (HYOU1) gene, with alleles present at heterozygous state in her asymptomatic 
parents (Figure 11). 
HYOU1 is a member of Hsp70 (70 kD heat shock protein) –family (Takeuchi, 2006). The Hsp70 
proteins participate in protein folding and cell stress responses(Mayer & Bukau, 2005; Young, 2010). 
They share a common domain structure, with peptide binding groove and alpha-helical lid 
participating in substrate binding and ATPase domain fueling the lid “opening” and “closure”(Mayer 
& Bukau, 2005; Takeuchi, 2006; Young, 2010). The mutations (chr11: 118922614 C>G, p.A419P and 
chr11:118924936 A>G, p.Y231H , Figure 11) localized to ATPase domain of HYOU1. Both mutations 
affected conserved residues, were predicted as damaging and were not present in major public and 
in-house databases. (E. Haapaniemi, et al., 2015) 
 
 
 
Figure 11. Upper panel: HYOU1 mutations in ATPase domain, with evolutionary conservation and 
mutation prediction scores (Poly-Phen and SIFT) shown. Below: family tree and the observed 
mutations shown in the patient and her parents.Figure modified from (E. Haapaniemi, et al., 2015) 
 
15.4 Functional consequences of HYOU1 dysfunction 
Since the mutations in were HYOU1 ATPase domain, it can be hypothesized that they impair ATP 
hydrolysis. This, in turn, could prevent the adequate conformational changes in peptide-binding 
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domain and alpha-helical lid, and prevent adequate substrate binding. To see whether substrate 
binding was altered, stable, tetracycline inducible HEK293 cell lines expressing C-terminally 
streptavidin-tagged WT, Y231H and A419P HYOU1 proteins were engineered. The induced proteins 
were subsequently immunoprecipitated and the resulting protein complexes analyzed with affinity-
purification mass spectrometry. The WT HYOU1 interacted with approximately 24 proteins with 
spectral count values > 1; of these, 20 were bound by either mutant with comparable affinity. In 
contrast, both mutants bound with high affinity to a range of proteins that did not bind to WT 
HYOU1. These results suggested that the binding profile was altered in mutated HYOU1 proteins, 
leading to ectopic protein binding (see Fig 12). (E. Haapaniemi, et al., 2015) 
15.4.1 RNA sequencing 
Increased endoplasmic reticulum stress and unfolded protein response is a major feature in severe 
congenital neutropenia pathogenesis (Glaubach et al., 2014; Hauck & Klein, 2013). To measure the 
effects of the Y231H and A419P mutations on cellular processes including apoptosis, ER stress and 
UPR, RNA sequencing was performed on patient and control primary skin fibroblasts with and 
without Tunikamycin, a compound that induces ER stress by impairing N-linked glycosylation. In 
steady state, the transcriptome suggested enhanced protein synthesis, glucose metabolism, and 
redox enzyme transcription in patient cells. Cell cycle and DNA replication -related transcripts were 
downregulated. Interestingly, several proteins that were identified as ectopic binding partners for 
Y231H and A419P mutations were upregulated in RNA sequencing. (E. Haapaniemi, et al., 2015) 
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Figure 12. Affinity-purification mass spectrometry of streptavidin-tagged WT, Y231H and A419P 
HYOU1 proteins demonstrate altered binding between mutant and WT HYOU1 proteins (upper 
panel). Some of the mutant HYOU1 binding partners were differentially expressed in RNA sequencing 
(lower panel, squared in the heatmap). Figure modified from (E. Haapaniemi, et al., 2015) 
Table 15. Pathway analysis results of differentially expressed genes in patient when compared to 
healthy controls (n=2). Pathway analysis was performed using DAVID bioinformatics database 
(Huang da et al., 2009). Representative pathways with p-value cutoff at 10-4 are shown. n=number 
of differentially expressed genes in the category. 
 Patient upregulated genes Patient downregulated genes 
Untreated n=376 
Protein biosynthesis (p<10-15) 
Ribosome (p<10-8) 
Actin binding and related (p<10-8) 
ECM and related (p<10-8) 
Glucose metabolism (p<10-6) 
Redox balance (p<10-5) 
 
n=98 
Cell cycle (p<10-7) 
Negative regulation of cell metabolism 
(p<10-5) 
Ribosome (p<10-4) 
DNA replication (p<10-4) 
Microtubulus and related (p<10-4) 
 
Tunicamycin n=169 
ECM and related (p<10-9) 
Actin-binding and related (p<10-6) 
Glucose metabolism (p<10-5) 
n=205 
Negative regulation of protein metabolism 
(p<10-7) 
Cell cycle (p<10-5) 
Cytoskeleton (p<10-4) 
 
15.4.2 Electron microscopy 
HYOU1 is localized to endoplasmic reticulum and mitochondria and implicated in cell stress 
responses (Arrington & Schnellmann, 2008; Ozawa et al., 1999; Takeuchi, 2006; Tamatani et al., 
2001). Extensive endoplasmic reticulum stress can be visualized by electron microscopy by looking 
for ER dilatation and protein accumulation (Donohoe, Mogelsvang, & Staehelin, 2006). Thus, patient 
and healthy control neutrophils were studied with immunofluorescence and electron microscopy. 
However, no difference in HYOU1 localization or ER size was noted. Instead, increased number of 
mitochondria was noted in patient neutrophils (Figure 13). The mitochondria were of normal size. 
(E. Haapaniemi, et al., 2015) 
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Figure 13. Frequency of mitochondria in patient vs control neutrophils. The mitochondrial frequency 
was estimated by comparing mitochondrial surface area (µm2) to cytoplasm surface area (upper 
panel). The patient neutrophils show increased number of mitochondria. The mitochondrial size is 
normal (lower panel). 
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15.4.3 Metabolomics 
The previous knowledge on HYOU1 function, as well as results derived from RNA sequencing, 
electron microscopy and mass spectrometry suggested that cell metabolism was altered in the 
patient. To evaluate this, targeted mass spectrometry on 101 common metabolites in patient and 
control primary fibroblasts was performed. Multiple pathways were altered, the most significant 
being related to redox metabolism. (E. Haapaniemi, et al., 2015) 
 
 
Figure 14. The ten most significantly altered metabolic pathways. 
Interestingly, enrichment in similar pathways was noted on all three high-throughput assays (see 
Table 16). The consistent finding was pathways related to redox metabolism. The role of redox 
balance in the disease pathogenesis was also supported by the increased mitochondrial number and 
reactive oxygen species production in patient neutrophils. (E. Haapaniemi, et al., 2015) 
Table 16. Comparison of enriched pathways in different high-throughput experiments.. 
 
Most genes that cause severe congenital neutropenia localize to endolysosomal compartment, and 
HYOU1 is no exception (Arrington & Schnellmann, 2008; Glaubach et al., 2014; Hauck & Klein, 2013; 
Ozawa et al., 1999; Takeuchi, 2006; Tamatani et al., 2001). HYOU1 functions as endoplasmic 
reticulum chaperone. It participates in protein folding, secretion and unfolded protein response 
signaling. It also localizes to mitochondria and likely participates in oxidative stress response. Its 
function thus resembles that of HAX1 and JAGN1, both of which directly participate in ER stress 
Pathway RNA-seq AP-mass spectrometry Metabolic assay 
Redox Redox balance (p<10-5) 
Intramolecular oxidoreductase 
activity (p<10-4) 
Glutathione metabolism 
(p<0.001) 
    
Cysteine metabolism 
(p<0.005) 
Protein synthesis 
Protein biosynthesis 
(p<10-15) Protein folding (p<0.05) RNA transcription (p=0.005) 
  Ribosome (p<10-8)  
Protein biosynthesis 
(p<0.05) 
Glucose 
metabolism 
Glucose metabolism 
(p<10-6) Glycolysis (p=0.08) 
Glucose-alanine cycle 
(p<0.05) 
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signaling and/or protein folding, and also have mitochondrial functions (Boztug et al., 2014; Hauck 
& Klein, 2013; Klein et al., 2007). Of all SCN gene defects, only HYOU1 seems to cause broad 
hematological abnormalities that predominantly affect the myeloid compartment (see Table 17). 
More patients are needed to define the exact phenotype. 
The common pathogenic mechanism for other endosomal SCN genes relates to endoplasmic 
reticulum stress, either by unfolded protein accumulation or heightened stress sensitivity(Boztug et 
al., 2014; Glaubach et al., 2014; Hauck & Klein, 2013). In our patient, we noted altered ER stress 
response when we stimulated primary fibroblasts with Tunikamycin, a compound that impairs N-
linked glycosylation. However, we also noted disturbances in redox balance in multiple high-
throughput assays, suggesting impaired mitochondrial function. The extent of the possible defect 
requires more studies.  It is likely that both altered ER and mitochondrial function and play a role in 
pathogenesis.  
In conclusion, HYOU1 is important for normal myelopoiesis, effective antigen presentation, and it 
also plays a role in B cell homeostasis. The pathogenic mechanism seems to be linked disturbed 
mitochondrial and endoplasmic reticulum homeostasis. Detailed studies and larger case series are 
needed to define the exact clinical phenotype and molecular pathogenesis of this novel syndrome.  
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16. Study limitations 
 
In this study, three novel primary immunodeficiency diseases have been characterized: STAT3 
hyperactivation syndrome that leads to multi-organ autoimmunity and mild immunodeficiency, 
DOCK2 deficiency that causes severe viral illness, and HYOU1 dysfunction which broadly affects the 
myeloid, and to a lesser extent, lymphoid compartment. 
The major pitfall in our study is the small size of patient cohorts, ranging from one to six cases. Given 
the rarity of the diseases, this is understandable. However, it is also problematic since PIDD genes 
give variable phenotypes, which is well illustrated when comparing the STAT3 cohorts in this and 
Milner studies. Moreover, biased patient collection might lead to overrepresentation of certain 
manifestations (ie. neonatal diabetes). More case series collected from different specialties and 
clinics are needed to better characterize the clinical and immunological phenotypes.  
For patients with STAT3 mutations, it is important to understand the prognostic factors for severe 
disease course. Current data does not support genotype-phenotype correlation but complex 
interplay between modifier genes and environmental factors. 
STAT3 is a well-studied oncogene, and multiple inhibitors of JAK-STAT pathway are being developed 
or in clinical trials. In the Milner cohort, a patient with activating STAT3 mutation had significant 
improvement of his autoimmune disease upon treatment with IL-6 inhibitor tocolituzumab, which 
targets upstream STAT3 signaling (Milner et al., 2015). In the future, clinical trials with STAT3 
signaling inhibitors are warranted. 
It is possible that when characterizing single patients – as in the case of HYOU1 abnormality – a 
wrong gene defect is identified as causative. Although several gene defects were originally described 
in single patients (Ciancanelli et al., 2015; Sharfe, Dadi, Shahar, & Roifman, 1997), it is important to 
find subsequent cases with phenotypes reminiscent of the index patient. Furthermore, rigorous 
functional testing is needed to prove causality. 
The functional studies presented here give strength for the mutant-phenotype causality but do not 
explain the immunological consequences in detail. Moreover, several studies are performed in cell 
lines such as HEK293, which poorly represent the human immune system. More studies, preferably 
using human subjects and primary cells, are warranted.  
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Conclusions 
 
In this thesis work, three novel primary immunodeficiency conditions have been genetically and 
immunologically characterized.  
First, activating STAT3 mutations were found from a total of six patients presenting with IPEX-like 
disease and lymphoproliferation. Additional work done by Milner et al. (Milner et al., 2015) 
identified an additional 13 patients with activating STAT3 mutations. From these studies we can 
conclude that STAT3 hyperactivation causes an immunodysregulatory syndrome with early-onset 
autoimmunity, lymphoproliferation, short stature and hypogammaglobulinemia as cardinal 
features. Additionally, some patients might experience opportunistic infections, such as invasive 
candida or mycobacterial diseases. The severity of the condition varies and is not correlated with 
mutation status; hence, additional genetic and environmental factors play a role. 
Then, combined immunodeficiency caused by loss-of-function DOCK2 mutations is characterized. 
The patients presented with early-onset invasive viral and bacterial infections. Immunologically, the 
patients show low T and B cell counts, defective NK cell function, and diminished antiviral interferon 
response. The condition is fatal without stem cell transplantation. 
Finally, a patient with microcytic anemia, intermittent thrombocytopenia, congenital neutropenia, 
granulocytopenia, dendritic cell and B cell deficiency was evaluated in this study. She suffered from 
recurrent bacterial and herpetic infections. She was found to carry recessive compound 
heterozygous mutations in HYOU1. Functionally, this led to alterations in endoplasmic reticulum 
stress response and redox balance. We conclude that HYOU1 is important for myeloid –and to a 
lesser extent lymphoid – cell differentiation. However, more patients are needed to define the 
clinical spectrum of this novel syndrome. 
This thesis work shows that exome sequencing can be used successfully for primary 
immunodeficiency diagnostics, and novel gene defects can be identified in situations where only a 
single affected patient is present. However, rigorous functional testing is needed to establish causal 
relationships in these cases.  
Due to continuously falling sequencing prices, whole genome sequencing will likely overtake exome 
sequencing, and the techniques will soon become routine clinical tests in genetic disease 
diagnostics. Compared to standard gene testing approaches, they’re superior in speed, accuracy, 
coverage, and cost. The data interpretation, however, is still difficult in many cases, and requires 
collaboration between clinicians, bioinformaticians, and basic scientists. (Biesecker & Green, 2014; 
Cooper & Shendure, 2011). 
It is likely that all monogenic diseases involving protein-coding alterations have been discovered by 
2020. Monogenic diseases involving regulatory regions, non-coding RNAs and other intergenic 
regions, however, still pose a challenge. As more monogenic diseases are being discovered, the 
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atypical presentations, genotype-phenotype correlations, and prognostic factors will gain more 
focus.  
As there is increasing supply for targeted therapies in cancer and autoimmune disease, accurate 
gene diagnosis sometimes allows for precision medicine that directly affects the faulty pathway 
(Glaser & Goldbach-Mansky, 2008; Hu & Gatti, 2008). The recent developments in genome editing 
technologies are also opening entirely new treatment avenues for human genetic diseases (Xiao-Jie, 
Hui-Ying, Zun-Ping, Jin-Lian, & Li-Juan, 2015). The upcoming years will be exciting for patients, 
clinicians, and scientists alike. 
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